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Summary 
Cancer cells are endowed with the capability to reprogram cell metabolism in order to 
support neoplastic growth and cell death escape. A key role in this process is played by 
signaling pathways, mainly cascades regulated by kinases. Integration of survival and 
death stimuli occurs on mitochondria, where many of these signals converge to the 
regulation of a channel, the permeability transition pore (PTP), that triggers mitochondrial 
depolarization and release of pro-apoptotic factors from mitochondria. PTP opening 
commits cells to death, and it is regulated by a variety of factors. Here I have studied how 
signal transduction pathways affect cell metabolism, particularly mitochondrial 
bioenergetics, which could eventually lead to modulation of PTP opening. 
In the first part of my work, I have explored the presence of the PTP in cells depleted of 
mitochondrial DNA (ρ0 cells) which lack respiration and constitute a model for the analysis 
of mitochondrial involvement in several pathological conditions, among which cancer. I 
have observed that these cells are indeed equipped with a functioning PTP, whose 
regulatory mechanisms are similar to those observed in cancer cells. In detail, inhibition 
of PTP opening is a survival mechanism achieved by two different mechanisms: the first 
one is the mitochondrial binding of the glycolytic enzyme hexokinase (HK) II, which is up-
regulated in ρ0 cells; the second one relies on the hyper-activation of the ERK-GSK3 
signaling pathway that converge on mitochondria where it maintains the PTP regulator 
cyclophilin D (CyP-D) in the dephosphorylated form. I observed that mitochondria of ρ0 
cells maintain a membrane potential which is readily dissipated after displacement of HK 
II from the mitochondrial surface by treatment with either the drug clotrimazole or with a 
cell-permeant HK II peptide, or by keeping ρ0 cells in serum and glucose starvation. The 
PTP inhibitor cyclosporin A (CsA) is able to decrease the mitochondrial depolarization 
induced by either HK II displacement or by nutrient depletion. Moreover, glucose and 
serum deprivation causes concomitant ERK1/2 inhibition and GSK3α/β activation with the 
ensuing phosphorylation of CyP-D and PTP opening. Indeed, GSK3α/β inhibition with 
indirubin-3′-oxime decreases PTP-induced cell death in ρ0 cells following nutrient 
ablation. 
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In the second part of my work, I have focused my attention on a tumor predisposition 
syndrome, called Neurofibromatosis type 1 (NF1), caused by loss of function of 
neurofibromin, which acts as a negative regulator of the Ras signaling cascades. Here I 
have investigated whether the Ras hyper-activation induced by neurofibromin ablation 
can affect mitochondria bioenergetics, thus contributing to the metabolic rewiring of NF1 
tumors. I observed that the absence of neurofibromin confers to mouse embryonic 
fibroblasts (MEFs) the capability to form colonies in an in vitro tumorigenesis assay, and 
that the use of an ERK inhibitor completely abrogates colony formation. Moreover, I 
injected wild-type and Nf1-/- MEFs subcutaneously into nude mice in order to test the 
capability of the cells to form tumors in vivo. I observed that the absence of Nf1 leads to 
the growth of a tumor mass within a month, whereas no tumor can be formed in the 
same time frame by wild-type MEFs. I started the analysis of mitochondrial bioenergetics 
by measurements of oxygen consumption rate (OCR) performed with an extracellular flux 
analyzer on adherent cell monolayers. Nf1-/- MEFs display a lower OCR than wild-type 
MEFs both in basal condition and upon treatment with a low concentration of an 
uncoupler, which stimulates respiration maximally. Moreover, I found that the fraction of 
oxygen consumption coupled to ATP production by mitochondrial ATP synthase is lower 
in cells without Nf1, suggesting that ATP requirements are mainly supplied by glycolysis. 
Accordingly, upon glucose starvation or inhibition of glycolysis with 5-thioglucose Nf1-/- 
cells display a stronger decrease in ATP levels compared to wild-type cells. The different 
OCRs between wild-type and Nf1-/- cells are not related to differences in mitochondrial 
mass or membrane potential. 
In order to establish whether a modulation of respiratory chain activity could account for 
the observed OCR differences, I analyzed the expression level of the respiratory chain 
complexes. Complex I (NADH dehydrogenase) is down-regulated by Nf1 ablation, as a 
lower level of some of its subunits and of the assembled complex I was detected. 
Furthermore, the enzymatic activity of complex I is expectedly lower in Nf1-/- cells. 
Interestingly, administration of an ERK inhibitor increases the expression of complex I 
subunits resulting in its augmented assembly and activity; remarkably, this effect is more 
pronounced in Nf1-/- MEFs than in wild-type cells. 
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I also observed down-regulation of complex II (succinate dehydrogenase) activity in 
knock-out cells compared to wild-type MEFs. Interestingly, I found that complex II 
interacts with the mitochondrial chaperone TRAP1 and the kinase ERK, a fraction of which 
is mitochondrial; these interactions are stronger in Nf1-/- than in wild-type cells, as 
assessed by blue native gel analysis. However, silencing of TRAP1 does not change the 
activity of complex II; in accordance to this, the OCR of cells in which TRAP1 has been 
down-regulated does not vary, yet modulation of TRAP1 levels affects maximal 
respiration of Nf1-/- cells. Interestingly, silencing of TRAP1 in Nf1-deficient MEFs 
compromises the tumorigenic properties of these cells.  
Taken together, these observations suggest that the absence of neurofibromin leads to a 
more glycolytic metabolism by down-modulating the activity of respiratory chain 
complexes. The metabolic switch observed upon Nf1 deletion is a typical marker of cancer 
cells that favors tumor progression. We hypothesize that Ras-ERK signaling is upstream to 
the regulation of mitochondrial bioenergetics, and that the metabolic changes prompted 
by Ras-ERK activation can contribute to the transformed phenotype that we observe in 
Nf1-/- MEFs. 
 
 
 
 
 
 
 
 
 
 
4 
 
Sommario 
Le cellule tumorali hanno la capacità di riprogrammare il metabolismo al fine di sostenere 
la crescita cellulare e di sfuggire ai segnali di morte. Un ruolo centrale in questo processo 
è a carico delle vie di segnale, principalmente regolate da chinasi. L’integrazione degli 
stimoli di morte e di sopravvivenza avviene nei mitocondri, dove molti di questi segnali 
convergono sulla regolazione di un canale, il poro di transizione di permeabilità (PTP), che 
è responsabile della depolarizzazione mitocondriale con il conseguente rilascio di fattori 
pro-apoptotici dall’organello. L’apertura del PTP porta le cellule alla morte ed è regolato 
da un’ampia varietà di fattori. In questo lavoro ho studiato come i meccanismi di 
trasduzione del segnale impattano sul metabolismo cellulare, in particolare sulla 
bioenergetica mitocondriale, giungendo quindi ad una modulazione dell’apertura del PTP. 
Nella prima parte del mio lavoro ho indagato la presenza del PTP in cellule depletate del 
DNA mitocondriale (cellule ρ0) che presentano una totale assenza della respirazione e 
costituiscono un buon modello per l’analisi del coinvolgimento dei mitocondri in molte 
condizioni patologiche tra cui il cancro. Ho osservato che queste cellule possiedono un 
PTP funzionale, i cui meccanismi di regolazione sono simili a quelli presenti nelle cellule 
tumorali. Nel dettaglio, l’inibizione dell’apertura del PTP è un meccanismo di 
sopravvivenza raggiunto attraverso due meccanismi: il primo riguarda la localizzazione 
mitocondriale dell’enzima glicolitico esochinasi (HK) II, che è over-espresso nelle cellule 
ρ0; il secondo meccanismo è basato sull’iper-attivazione della via di segnale ERK-GSK3 che 
converge sui mitocondri dove mantiene il regolatore del poro, la ciclofilina D (CyP-D), 
nello stato defosforilato e quindi inattivo. Ho osservato che i mitocondri delle cellule ρ0 
mantengono un potenziale di membrane che è dissipato in seguito alla dislocazione del 
HK II dalla superficie mitocondriale attraverso trattamento con clotrimazolo o tramite 
l’uso di un peptide che permea le membrane, o, in alternativa, a seguito di deplezione di 
siero e glucosio. L’inibitore del poro, la ciclosporina A (CsA), è in grado di diminuire la 
depolarizzazione mitocondriale indotta dalla dislocazione del HK II o dalla deplezione di 
nutrienti. Inoltre, la deplezione di siero e glucosio causa una concomitante inibizione di 
ERK1/2, un’attivazione di GSK3α/β e una conseguente fosforilazione di CyP-D con 
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apertura del PTP. Infatti, inibendo GSK3α/β con l’indirubina, la morte cellulare causata 
dall’apertura del poro in seguito a deprivazione di nutrienti è diminuita. 
Nella seconda parte del mio lavoro mi sono focalizzata su una sindrome che predispone i 
pazienti all’insorgenza di tumori, la Neurofibromatosi di tipo 1, causata da perdita di 
funzione della neurofibromina, un regolatore negativo della via di segnale dominata da 
Ras. Ho studiato la possibilità che l’iper-attivazione della via di Ras dovuta all’inattivazione 
della neurofibromina possa modificare la bioenergetica mitocondriale, contribuendo così 
a cambiamenti metabolici in tumori di pazienti con NF1. Ho osservato che l’assenza della 
neurofibromina in fibroblasti embrionali di topo (MEFs) conferisce la capacità di formare 
colonie in un saggio tumorigenico in vitro, mentre il trattamento con un inibitore di ERK 
inibisce la formazione delle colonie in modo significativo. Inoltre, ho iniettato queste 
cellule sotto cute in topi nudi al fine di testare il loro potenziale tumorigenico in vivo. Ho 
osservato che l’assenza di neurofibromina porta alla crescita di una massa tumorale 
nell’arco di un mese dall’iniezione, mentre non si osservano masse tumorali nel caso di 
cellule wild-type. Ho iniziato l’analisi del profilo bioenergetico mitocondriale misurando il 
consumo di ossigeno in cellule adese ed ho osservato che cellule senza neurofibromina 
presentano un diminuito tasso di respirazione basale, oltre che una minore respirazione 
massima raggiunta dopo trattamento con basse concentrazioni di un disaccoppiante. 
Inoltre, la frazione di respirazione accoppiata alla produzione di ATP da parte dell’ATP 
sintasi è minore nelle cellule senza neurofibromina, suggerendo che le richieste 
energetiche sono principalmente a carico della glicolisi. In accordo a questi dati, in seguito 
a deplezione di glucosio o all'inibizione della glicolisi con 5-tioglucosio le cellule assenti 
della neurofibromina presentano un maggiore calo nei livelli di ATP rispetto a cellule wild-
type. Le differenze del consumo di ossigeno, inoltre, non sono dovute a cambiamenti 
nella massa mitocondriale o nel potenziale di membrana. 
Al fine di determinare se possibili differenze nell’attività della catena respiratoria siano la 
causa di una diversa respirazione, ho analizzato l’espressione proteica di diverse subunità 
dei complessi respiratori. Il complesso I (NADH deidrogenasi) è diminuito in seguito alla 
deplezione della neurofibromina, così come la sua attività. Inoltre, la repressione 
farmacologica di ERK in cellule knock-out è in grado di aumentare specificatamente 
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l’espressione delle subunità del complesso I, e quindi la sua attività; al contrario, questo 
effetto è meno forte nelle cellule wild-type. 
Ho osservato anche una diminuita attività del complesso II (succinato deidrogenasi) nelle 
cellule knock-out. Inoltre, ho trovato un’interazione tra il complesso II, lo sciaperone 
mitocondriale TRAP1 e la chinasi ERK, una frazione della quale è stata trovata nei 
mitocondri; queste interazioni sono molto più forti nelle cellule knock-out rispetto a 
quelle wild-type. Tuttavia, il silenziamento di TRAP1 non causa una variazione dell’attività 
del complesso II, bensì un’aumentata respirazione massima nelle cellule senza 
neurofibromina. Inoltre, la diminuita espressione di TRAP1 causa la perdita del potenziale 
tumorigenico delle cellule knock-out. 
Questi risultati suggeriscono che l’assenza della neurofibromina porta ad un fenotipo 
glicolitico con una diminuzione della respirazione mitocondriale. Questo cambiamento 
metabolico è tipico delle cellule tumorali poiché favorisce la progressione tumorale. 
Abbiamo quindi ipotetizzato che i cambiamenti metabolici causati dall’iper-attivazione 
della via di segnale Ras-ERK possano contribuire al fenotipo trasformante che abbiamo 
osservato nelle cellule senza neurofibromina. 
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1.1. The hallmarks of cancer 
Cancer cells are characterized by changes in a variety of intrinsic biological processes and 
in environmental interactions that lead to loss of tissue homeostasis. In 2000 it has been 
proposed that six essential alterations in cell physiology collectively dictate malignant 
growth of most and perhaps all types of cancers (Hanahan and Weinberg, 2000): self-
sufficiency in growth signals, insensitivity to growth-inhibitory (anti-growth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Fig. 1). Each of these physiologic 
changes represents the successful breaching of an anticancer defense mechanism. 
Indeed, cancer development requires complex heterotypic interactions among neoplastic 
cells and several other cell types in the tumor microenvironment which act as active 
participants rather than passive bystanders in tumorigenesis. 
  
Figure 1. The Hallmarks of Cancer. This illustration was originally proposed in 2000 by Hanahan and Weinberg and 
encompasses the six hallmark capabilities of cancer cells (Hanahan and Weinberg, 2000). 
Conceptual progress in the last decade has added two emerging hallmarks of potential generality 
to this list (Hanahan and Weinberg, 2011). One involves the capability to modify, or reprogram, 
cellular metabolism in order to most effectively support neoplastic proliferation. The second 
allows cancer cells to evade immunological destruction; this feature highlights the dichotomous 
roles of an immune system that might both antagonize and enhance tumor development and 
progression (Fig. 2). Additionally, two consequential characteristics of neoplasia facilitate 
acquisition of both core and emerging hallmarks. Genomic instability and thus mutability endows 
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cancer cells with genetic alterations that drive tumor progression. Inflammation by innate 
immune cells designed to fight infections and heal wounds can instead result in their inadvertent 
support of multiple hallmark capabilities, thereby manifesting the now widely appreciated tumor-
promoting consequences of inflammatory responses. 
 
Figure 2. Emerging Hallmarks and Enabling Characteristics. Two additional hallmarks of cancer are involved in the 
pathogenesis of some and perhaps all cancers: reprogramming of energy metabolism and evading immune destruction. 
Genomic instability and tumor-promoting inflammation work as enabling characteristics for the acquisition of the 
hallmark properties of cancer cells (Hanahan and Weinberg, 2011). 
Even though these features of cancer cells are depicted as distinct properties which can 
be acquired at different time points of the tumorigenic process, they are finely inter-
regulated and the alteration of one of these physiological changes is able to strongly 
impact on the others. It follows that the boundary line between one property and the 
other is very labile, adding further complexity to the system. 
1.2.  Tumor metabolism 
Tumor cells have a remarkably different metabolism from that of the tissues which they 
are derived from. Indeed, the metabolism of neoplastic cells must sustain higher 
proliferative rates and resist oxygen paucity found in the inner tumor mass; at the same 
time, neoplasms are continuously exposed to oxidative insults (Tennant et al., 2009).  
Last century, Otto Warburg made pioneering and substantial contributions to our early 
understanding of cancer metabolism. He measured oxygen consumption and lactate 
production in tumor slices, either in the presence or absence of oxygen, finding that 
rapidly growing tumor cells consumed glucose at a surprisingly high rate compared to 
normal cells in the presence of oxygen, and most of the glucose-derived carbon was 
10 
 
secreted by neoplasms in the form of lactate (Warburg et al., 1927). Warburg later 
postulated that this phenomenon, termed ‘aerobic glycolysis’, was provoked by 
mitochondrial impairment and was the origin of cancer cell transformation (WARBURG, 
1956a; WARBURG, 1956b) promoting the erroneous idea that damaged respiration is the 
sine qua non for neoplastic transformation. Several further metabolic alterations and 
adaptations of cancer cells have been discovered in the following decades (Fig. 3) 
(Tennant et al., 2010). Nonetheless, starting from the seventies of last century, the 
oncogene revolution, i.e. the discovery of genes whose mutations could prompt 
tumorigenesis (Hunter, 1997; Knudson, 2002), pushed tumor metabolism to the margins 
of cancer research. Warburg’s observations were almost forgotten for a long period, and 
the metabolic alterations of tumors were simply considered an epiphenomenon of 
changes elicited in the neoplastic cells by mutations in oncogenes and tumor suppressor 
genes. 
 
Figure 3. Timeline indicating some important advances in understanding and targeting tumor metabolism (Tennant et 
al., 2010). 
In the same period, Crabtree observed that increased glucose availability boosts glycolysis 
in cancer and normal proliferating cells, while inhibiting respiration, an observation now 
known as the ‘Crabtree effect’ (Crabtree, 1928). He further suggested that this 
observation is sufficient to explain the decrease in oxidative phosphorylation (OXPHOS)-
derived ATP in cancer, which argues against Warburg’s initial hypothesis that defects in 
respiration are the cause for increased glycolysis. Years later it was suggested that 
respiration inhibition by glycolysis was caused by glycolysis competing with OXPHOS for 
phosphate and ADP. However, the Crabtree effect does not provide an explanation for 
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the actual cause of the observed increased aerobic glycolysis in cancer (Frezza and 
Gottlieb, 2009). 
Subsequent work showed that mitochondrial function is not impaired in most cancer 
cells, suggesting that the shift towards glycolysis during neoplastic transformation occurs 
as a consequence of regulatory mechanisms. 
 
Figure 4. ATP yield of OXPHOS, anaerobic glycolysis and aerobic glycolysis (Warburg Effect) (Vander Heiden et al., 
2009). 
We still do not understand exactly what is the advantage obtained by tumor cells in 
moving their metabolic demand towards glucose usage (Fig. 4). In many cancer cells, 
bioenergetic reprogramming involves switching from the maximal ATP production by 
OXPHOS in quiescent or differentiated cells to the requirement for balancing energy 
needs with substrate generation for cellular biogenesis and reproduction in rapidly 
growing cells. The current model postulates that the preferential use of aerobic glycolysis 
offers the following advantages to highly proliferative cells. First, it focuses cells on the 
use of glucose, which is the most abundant extracellular nutrient; second, the flux of ATP 
derived from glycolysis can exceed the one produced during OXPHOS, despite the low 
efficiency of glycolysis, when glucose is provided at a sufficiently high concentration; 
third, glucose utilization provides essential metabolic intermediates for the biosynthesis 
of diverse macromolecules (lipids, proteins and nucleic acids) and for anti-oxidative 
defenses, with the production of NADPH (Fig. 5) (Lunt and Vander Heiden, 2011; Vander 
Heiden et al., 2009). 
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Figure 5. Tumor cells obtain biosynthetic precursors from glucose and glutamine metabolism. Glucose and glutamine, 
the two most abundant extracellular nutrients, contribute carbon for the synthesis of the three major classes of 
macromolecules (nucleic acids, lipids, and proteins) in proliferating tumor cells. Biosynthesis of purines and pyrimidines 
utilizes ribose 5-phosphate (R5P) produced from diversion of glycolytic intermediates into the oxidative and non-
oxidative arms of the pentose phosphate pathway, and nonessential amino acids derived from glucose and glutamine. 
Fatty acid synthesis, used to produce cellular lipids, requires acetyl-CoA (Ac-CoA), most of which is generated from 
glucose and transferred from the mitochondria to the cytoplasm via citrate. Protein synthesis requires amino acids, 
tRNAs and ribosomes (proteins and rRNAs). Both glucose and glutamine are used to generate these molecules. In 
addition to its role as a carbon source, glutamine also donates nitrogen to nucleotide and amino acid synthesis. 
Abbreviations: P, phosphate; GA3P, glyceraldehyde 3-phosphate; 3-PG, 3-phosphoglycerate; PRPP, phosphoribosyl 
pyrophosphate; Mal-CoA, malonyl-CoA (Deberardinis et al., 2008). 
Multiple molecular mechanisms, both intrinsic and extrinsic, converge to alter core 
cellular metabolism and provide support for the basic needs of dividing cells (Fig. 6). 
Therefore, metabolic adaptation in tumors extends beyond the Warburg effect and, 
besides aerobic glycolysis, there are other core fluxes, such as the pentose phosphate 
pathway, the de novo fatty acid synthesis and glutamine-dependent metabolism that 
cancer cells need for their high rate of replication. On the basis of these observations, the 
development of treatments that target tumor metabolism is receiving increasing 
attention, with several potential drugs targeting metabolic pathways currently in clinical 
trials. 
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Figure 6. Determinants of the tumor metabolic phenotype. Abnormal metabolic phenotype sustains cell growth by 
providing rapid ATP generation to maintain energy status, increased biosynthesis of macromolecules and tightened 
maintenance of appropriate cellular redox status (Cairns et al., 2011). 
1.2.1. Oncogene/tumor suppressor genes and cancer metabolism 
Some of the mechanisms used by tumors to bring about metabolic changes include the 
altered expression, mutation or post-translational inactivation of an enzyme or the 
substitution of an enzyme isoform with a different one. Notably, most tumor suppressor 
genes and oncogenes play a role in this neoplastic metabolic rewiring (Fig. 7) (Ward and 
Thompson, 2012).  
  
Figure 7. Molecular mechanisms driving the Warburg effect. Relative to normal cells (part a) the shift to aerobic 
glycolysis in tumor cells (part b) is driven by multiple oncogenic signaling pathways. PI3K activates AKT, which stimulates 
glycolysis by directly regulating glycolytic enzymes and by activating mTOR. The liver kinase B1 (LKB1) tumor 
suppressor, through AMP-activated protein kinase (AMPK) activation, opposes the glycolytic phenotype by inhibiting 
mTOR. mTOR alters metabolism in a variety of ways, but it has an effect on the glycolytic phenotype by enhancing 
hypoxia-inducible factor 1 (HIF1) activity, which engages a hypoxia-adaptive transcriptional program. HIF1 increases the 
expression of glucose transporters (GLUT), glycolytic enzymes and pyruvate dehydrogenase kinase, isozyme 1 (PDK1), 
which blocks the entry of pyruvate into the tricarboxylic acid (TCA) cycle. MYC cooperates with HIF in activating several 
genes that encode glycolytic proteins, but also increases mitochondrial metabolism. The tumor suppressor p53 opposes 
the glycolytic phenotype by suppressing glycolysis through TP53-induced glycolysis and apoptosis regulator (TIGAR), 
increasing mitochondrial metabolism via SCO2 and supporting expression of PTEN. OCT1 (also known as POU2F1) acts in 
an opposing manner to activate the transcription of genes that drive glycolysis and suppress OXPHOS. The switch to the 
pyruvate kinase M2 (PKM2) isoform affects glycolysis by slowing the pyruvate kinase reaction and diverting substrates 
into alternative biosynthetic and reduced nicotinamide adenine dinucleotide phosphate (NADPH)-generating pathways. 
MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase. The dashed lines indicate loss of p53 function 
(Cairns et al., 2011). 
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1.2.1.1. HIF and MYC 
The HIF1 and HIF2 complexes are the major transcription factors that are responsible for 
gene expression changes during the cellular response to low oxygen conditions (Bertout 
et al., 2008). They are heterodimers that are composed by the constitutively expressed 
HIF1β (also known as ARNT) subunit, and either the HIF1α or the HIF2α (also known as 
EPAS1) subunits. Under normoxic conditions, the HIFα subunits undergo oxygen-
dependent hydroxylation by prolyl hydroxylase enzymes, which results in their 
recognition by von Hippel-Lindau tumor suppressor (VHL), an E3 ubiquitin ligase, and 
subsequent degradation. HIFα subunits are rapidly stabilized either upon exposure to 
hypoxia, e.g. in the interior of the tumor mass, or under normoxic conditions by 
oncogenic signaling pathways, including PI3K, and by mutations in tumor suppressor 
proteins such as VHL, succinate dehydrogenase (SDH) and fumarate hydratase (FH) 
(Semenza, 2010).  
Once activated, HIF1 enhances the transcription of genes encoding glucose transporters 
and most glycolytic enzymes, increasing the capacity of the cell to carry out glycolysis. In 
addition, HIF1 activates the pyruvate dehydrogenase kinases (PDKs), which inactivate the 
mitochondrial pyruvate dehydrogenase complex and thereby reduce the flow of glucose-
derived pyruvate into the tricarboxylic acid (TCA) cycle. This reduction in pyruvate flux 
into the TCA cycle decreases the rate of OXPHOS and oxygen consumption, reinforcing 
the glycolytic phenotype and sparing oxygen under hypoxic conditions (Kim et al., 2006; 
Papandreou et al., 2006). Inhibitors of HIF1 or of the PDKs could potentially reverse some 
of the metabolic effects of HIF1 signaling and several such candidates, including the PDK 
inhibitor dichloroacetic acid (DCA), are currently under evaluation as anti-neoplastic 
agents (Onnis et al., 2009). 
The first documented direct mechanistic link between an activated oncogene and altered 
glucose metabolism was the observation that lactate dehydrogenase isoform A (LDHA) is 
induced by the transcription factor MYC, whose deregulated activation is mandatory for 
the progression of a variety of malignancies (Dang et al., 2009). MYC and HIF1 share many 
target glycolytic enzyme genes, and MYC can activate most glycolytic enzyme genes as 
well as glucose transporters. Pyruvate kinase M2 (PKM2), which converts 
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phosphoenolpyruvate to pyruvate, replaces by alternative splicing PKM1 during cellular 
transformation and favors aerobic glycolysis (Christofk et al., 2008). MYC is able to induce 
the splicing factors that produce PKM2, further underscoring its role in cell metabolism. 
MYC also increases glutamine uptake by directly inducing the expression of the glutamine 
transporters SLC5A1 and SLC7A1 (also known as CAT1). Furthermore, MYC indirectly 
increases the level of glutaminase 1 (GLS1), the first enzyme of glutaminolysis, by 
repressing the expression of microRNA‑23A and microRNA‑23B, which inhibit GLS1. MYC 
may support antioxidant capacity by driving pentose phosphate pathway (PPP) based 
NADPH production through promoting the expression of the PKM2 isoform, thus diverting 
glucose usage from the Krebs cycle to the PPP (see Fig. 5), and also by increasing the 
synthesis of GSH through glutaminolysis. Moreover, once glutamine is converted into 
glutamate and then into α-ketoglutarate it can enter the TCA cycle. This process of 
anaplerosis supplies the carbon atoms required for the biosynthesis of both amino acids 
and fatty acids (DeBerardinis et al., 2007). 
1.2.1.2. p53 and OCT1 
Although the p53 tumor suppressor has been mainly regarded as the ‘guardian of the 
genome’, its function extends to regulation of cell metabolism by stimulating 
mitochondrial respiration and suppressing glycolysis through transcriptional regulation 
(Vousden and Ryan, 2009). p53 activates the expression of HK II, which converts glucose 
to glucose-6-phosphate (G6P). G6P then enters either glycolysis to produce ATP, or the 
PPP, which supports macromolecular biosynthesis by producing reducing potential in the 
form of NADPH and/or ribose, the building blocks for nucleotide synthesis. At the same 
time, p53 suppression of phosphoglycerate mutase 2 (PGAM2) and activation of tumor 
protein 53‑induced glycolysis and apoptosis regulator (TIGAR), which has 2,6‑fructose-
bisphosphatase activity and depletes PFK1 of a potent positive allosteric ligand, 
suppresses glycolysis and favors increased NADPH production by the PPP. Moreover, 
activation of SCO2 (which regulates the cytochrome c oxidase complex) by p53 increases 
the efficiency of mitochondrial respiration. Hence, loss of p53 function might be a major 
force behind the acquisition of the glycolytic phenotype (Jones and Thompson, 2009). 
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OCT1 (also known as POU2F1) is a transcription factor, the expression of which is 
increased in several human cancers, and it may cooperate with p53 in regulating the 
balance between oxidative and glycolytic metabolism. Data from studies of knockout 
mice and human cancer cell lines show that the transcriptional program that is 
orchestrated by OCT1 cooperates with the loss of p53, as it supports resistance to 
oxidative stress, increases glucose metabolism and inhibits mitochondrial respiration 
(Shakya et al., 2009). One of the OCT1 targets is an isoform of PDK (PDK4) that has the 
same function as the PDK enzymes that are activated by HIF1. Although the mechanisms 
by which OCT1 is up-regulated in tumor cells are poorly understood, its downstream 
effectors may be potential targets for therapeutic intervention. 
1.2.1.3. The PI3K pathway 
The PI3K pathway is one of the most commonly activated signaling pathways in human 
cancers by mutations in tumor suppressor genes, such as PTEN, in the components of the 
PI3K complex itself or by aberrant upstream signaling from receptor tyrosine kinases 
(Wong et al., 2010). Once activated, the PI3K pathway not only provides strong growth 
and survival signals to tumor cells but also has profound effects on their metabolism. The 
best-studied effector downstream of PI3K is AKT1 (also known as PKB). The increased and 
prolonged AKT1 signaling that is associated with transformation is an important driver of 
the tumor glycolytic phenotype through activation of hexokinase 2 (HK II) and 
phosphofructokinase 1 (PFK1; also known as PFKM) and PFK2 (also known as PFKFB3), 
recruitment of glucose transporters to the cell surface, and inhibition of forkhead box 
subfamily O (FOXO) transcription factors. AKT1 also activates ectonucleoside triphosphate 
diphosphohydrolase 5 (ENTPD5), an enzyme that supports increased protein glycosylation 
in the endoplasmic reticulum and indirectly increases glycolysis by creating an ATP 
hydrolysis cycle. Finally, AKT1 strongly stimulates signaling by the kinase mTOR by 
phosphorylating and inhibiting its negative regulator tuberous sclerosis 2 (TSC2; also 
known as tuberin) (Robey and Hay, 2009). mTOR functions as a key metabolic integration 
point, coupling growth signals to nutrient availability. Activated mTOR stimulates protein 
and lipid biosynthesis and cell growth in response to sufficient nutrient and energy 
conditions and is often constitutively activated during tumorigenesis (Guertin and 
Sabatini, 2007). At the molecular level, mTOR directly stimulates mRNA translation and 
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ribosome biogenesis, and indirectly causes other metabolic changes by activating 
transcription factors such as hypoxia-inducible factor 1 (HIF1) even under normoxic 
conditions. The subsequent HIF1-dependent metabolic changes further amplify the 
glycolytic phenotype elicited by PI3K, AKT1 and mTOR (see Fig. 5). 
1.2.1.4. AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is a crucial sensor of energy status and has an 
important pleiotropic role in cellular responses to metabolic stress (Shackelford and 
Shaw, 2009). The AMPK pathway couples energy status to growth signals; biochemically, 
AMPK opposes the effects of AKT1 and acts as a potent inhibitor of mTOR. The AMPK 
complex thus functions as a metabolic checkpoint, regulating the cellular response to 
energy availability. During periods of energetic stress, AMPK becomes activated in 
response to an increased AMP/ATP ratio, and is responsible for shifting cells to an 
oxidative metabolic phenotype and inhibiting cell proliferation. Tumor cells must 
overcome this checkpoint in order to proliferate in response to activated growth signaling 
pathways, even in a less than ideal microenvironment. Several oncogenic mutations and 
signaling pathways can suppress AMPK signaling, which uncouples fuel signals from 
growth signals, allowing tumor cells to divide under abnormal nutrient conditions (Wang 
and Guan, 2009). Given the role of AMPK, it is not surprising that STK11, which encodes 
liver kinase B1 (LKB1) — the upstream kinase necessary for AMPK activation — has been 
identified as a tumor suppressor gene and is mutated in Peutz–Jeghers syndrome, which 
is characterized by the development of benign gastrointestinal and oral lesions and an 
increased risk of developing a broad range of malignancies. LKB1 is also frequently 
mutated in sporadic cases of non-small-cell lung cancer and cervical carcinoma. Recent 
evidence suggests that LKB1 mutations are tumorigenic owing to the resulting decrease in 
AMPK signaling and loss of mTOR inhibition (Shackelford and Shaw, 2009). Clinically, 
there is currently considerable interest in evaluating whether AMPK agonists can be used 
to re-couple fuel and growth signals in tumor cells and to shut down cell growth. Two 
such agonists are the commonly used anti-diabetic drugs metformin and phenformin (Kim 
and He, 2013). It remains to be seen whether these agents represent a useful class of 
metabolic modifiers with antitumor activity. 
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1.2.1.5. Ras signaling pathway 
Ras proteins are signal switch molecules that regulate cell fate by coupling receptor 
activation to downstream effector pathways that control diverse cellular responses 
including proliferation, differentiation and survival. Ras proteins are small GTPases that 
cycle between inactive guanosine diphosphate (GDP)-bound and active guanosine 
triphosphate (GTP)-bound conformations (Ras-GDP and Ras-GTP, respectively). Growth 
factor binding to cell-surface receptors creates intracellular docking sites for adaptor 
molecules and signal-relay proteins that recruit and activate guanine nucleotide-exchange 
factors (GEFs), such as members of the SOS family. GEFs displace guanine nucleotides 
from Ras and permit passive binding to GTP, which is abundant in the cytosol, leading to 
Ras activation. Conversely, Ras proteins are negatively regulated by GTPase activating 
proteins (GAPs), which markedly stimulate intrinsic GTPase activity by stabilizing a high-
energy transition state that occurs during the Ras-GTP hydrolysis reaction (Malumbres 
and Barbacid, 2003; Schubbert et al., 2007). 
Ras-GTP regulates a complex signaling network that modulates cell behavior by binding to 
and activating distinct classes of effector molecules. The Raf-MEK-ERK cascade is the best 
characterized Ras effector pathway (McCubrey et al., 2007). ERK kinases can 
phosphorylate both cytosolic and nuclear substrates, which include transcription factors 
such as JUN and ELK1 that regulate FOS expression. Activation of these transcriptional 
regulators can lead to the expression of proteins that control cell-cycle progression, such 
as cyclin D. Ras-GTP also binds the catalytic subunit of type I PI3Ks leading to the 
translocation of PI3K to the plasma membrane and subsequent activation of downstream 
kinases such as AKT. PI3K also activates Rac, a Rho family GTPase, which has been shown 
to be important for transformation by oncogenic Ras in some cellular contexts. Ras can 
also activate a family of exchange factors for the Ral small GTPases (RalGEFs), which 
activate Ral leading therefore to stimulation of phospholipase D (PLD) (Fig. 8). 
Many other effector pathways are directly coupled to Ras-GTP, several of which have 
known roles in regulating cellular responses. Ras-GTP directly binds to the Rac exchange 
factor tumor invasion and metastasis inducing protein 1 (TIAM1), leading to increased 
levels of Rac and subsequent actin reorganization. Phospholipase Cε also binds directly to 
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Ras-GTP, and the consequent hydrolysis of PIP2 to diacylglycerol (DAG) and inositol-1,4,5-
triphosphate (Ins(1,4,5)P3) serves to release Ca
2+ and activate protein kinase C (PKC) 
(Karnoub and Weinberg, 2008). 
 
Figure 8. Ras signaling network. Ras proteins function as nucleotide-driven switches that relay extracellular cues to 
cytoplasmic signaling cascades. The binding of GTP to Ras proteins locks them in their active state, which enables high 
affinity interactions with downstream effectors. GTPase-activating proteins (GAPs), such as p120GAP or neurofibromin 
(NF1), enhance the intrinsic GTPase activity and hence negatively regulate Ras protein function. Conversely, guanine-
nucleotide exchange factors (GEFs), such as RasGRF and son of sevenless (SOS), catalyse nucleotide ejection and 
therefore facilitate GTP binding and protein activation. The classical view of Ras signaling depicts Ras activation and 
recruitment to the plasma membrane following receptor Tyr kinase (RTK) stimulation by growth factors (GF). Activated 
Ras engages effector molecules — belonging to multiple effector families — that initiate several signal-transduction 
cascades. Activating mutations in the different components of the Ras signaling pathway are associated with different 
developmental disorders, such as Neurofibromatosys type-1, cardio-facio-cutaneous (CFC), Noonan, Leopard and 
Costello syndromes (Karnoub and Weinberg, 2008). 
Mammalian genomes encode three RAS genes that give rise to four gene products: N-Ras, 
H-Ras, K-Ras4A, and K-Ras4B. K-Ras4A and K-Ras4B isoforms result from alternative 
splicing of the KRAS gene. Human cancers frequently express mutant Ras proteins, 
termed ‘oncogenic Ras’. Specific Ras genes are mutated in different malignancies: KRAS 
mutations are prevalent in pancreatic, colorectal, endometrial, biliary tract, lung and 
cervical cancers; KRAS and NRAS mutations are found in myeloid malignancies; and NRAS 
and HRAS mutations predominate in melanoma and bladder cancer, respectively. In most 
cases, the somatic missense Ras mutations found in cancer cells introduce amino acid 
substitutions at positions 12, 13 and 61. These changes impair the intrinsic GTPase 
activity and confer resistance to GAPs, thereby causing cancer-associated mutant Ras 
proteins to accumulate in the active, GTP-bound conformation (Schubbert et al., 2007). 
RAS can also be activated in tumors by loss of GAPs. The most significant known example 
is the loss of neurofibromin, which is encoded by the NF1 gene and has all the 
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characteristics of a tumor suppressor. Moreover, RAS signaling pathways are also 
commonly activated in tumors in which growth-factor-receptor tyrosine kinases have 
been hyper-activated. The most common examples are EGFR and ERBB2 (also known as 
HER2/neu), which are frequently activated by overexpression in many types of cancer, 
including breast, ovarian and stomach carcinomas (Downward, 2003). 
Hyper-activation of RAS signaling has a key role in the establishment of many abnormal 
functional properties of cancer cells, such as deregulated cell growth, survival and 
differentiation. Moreover, in the very last years, an increasing number of observations 
has highlighted the effect of oncogenic RAS signaling on tumor metabolism. An inducible 
KrasG12V system revealed that Ras-induced mitochondrial dysfunction precedes the 
activation of glycolysis, suggesting that mitochondrial dysfunction is causally associated to 
the metabolic switch observed in cancer (Hu et al., 2012). Moreover, integrated genomic, 
biochemical and metabolomic analyses following KrasG12D withdrawal in a pancreatic 
ductal adenocarcinoma model revealed a prominent perturbation of multiple metabolic 
pathways. In particular, KrasG12D exerts potent control of glycolysis through regulation 
of glucose transporter and several rate-limiting enzymes at the transcriptional level, 
which collectively serve to shunt glucose metabolism toward anabolic pathways, such as 
the hexosamine biosynthesis pathway (HBP) for protein glycosylation and the PPP for 
ribose production (Fig. 9) (Ying et al., 2012). 
 
Figure 9. Schematic representation of the shift in glucose metabolism upon KrasG12D withdrawal. Activation of 
oncogenic Kras enables pancreatic ductal adenocarcinoma (PDAC) tumor maintenance through the increased uptake of 
glucose and subsequent shunting into glycolysis, the HBP pathway (to enable enhanced glycosylation) and the non-
oxidative arm of the PPP (to facilitate ribose biosynthesis for DNA/RNA). Glucose flux into the oxidative arm of the PPP 
and the TCA cycle does not change when KrasG12D is inactivated (Ying et al., 2012). 
Furthermore, Ras was shown to transcriptionally regulate several components of the 
autophagy machinery (Elgendy et al., 2011). Interestingly, inhibition of autophagy in Ras-
transformed cells causes a striking accumulation of dysfunctional mitochondria, 
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suggesting that Ras might be responsible for early mitochondria dysfunction and that 
maintaining oxidative metabolism by increasing the clearance of dysfunctional 
mitochondria is critical (Guo et al., 2011). 
The impact of RAS signaling on tumor metabolism is a relatively new field and more 
studies have to be carried out in order to elucidate which are the downstream pathways 
responsible for metabolism rewiring upon Ras activation. The PI3K/AKT pathway is a good 
candidate as its impact on cellular metabolism has already been established; however, 
additional signaling pathways could take part to the metabolic shift observed in tumor 
cells following Ras activation. An interesting work showed that the activation of the MEK-
ERK pathway following growth factor stimulation can trigger the Warburg effect through 
modulation of the phosphorylation status of PKM2 (Yang et al., 2012). Indeed, 
phosphorylated PKM2 migrates to the nucleus where it leads to β-catenin transactivation 
and induction of c-Myc expression, which in turn up-regulates the expression of glycolytic 
enzymes (Fig.10). 
 
Figure 10. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. 
EGFR activation in human cancer cells induces PKM2 nuclear translocation, which is mediated by PKM2 phosphorylation 
by ERK, followed by PIN1-regulated cis-trans isomerization of PKM2 and subsequent binding to importin 5. Nuclear 
PKM2 is required for EGF-induced-catenin transactivation and induction of c-Myc expression, which in turn and thereby 
up-regulates the expression of glycolytic enzymes such as GLUT1, LDHA and also the PTB-dependent expression of 
PKM2 (Yang et al., 2012). 
1.2.2. Metabolic adaptation and microenvironment 
In addition to genetic changes, the abnormal tumor microenvironment has a major role in 
determining the metabolic phenotype of tumor cells. Tumor vasculature is structurally 
and functionally abnormal, and combined with intrinsically altered tumor cell 
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metabolism, creates spatial and temporal heterogeneity in oxygenation, pH, and the 
concentration of glucose and many other metabolites. These extreme conditions induce a 
collection of cellular stress responses that further contribute to the distorted metabolic 
phenotype of tumor cells and influence tumor progression. The response to hypoxia is the 
best studied of tumor cell stress responses owing to the well-known effects of hypoxia on 
tumor radio-resistance and metastasis. Other metabolic stress conditions such as low pH 
and low glucose are also prevalent in solid tumors and are likely to be major determinants 
of the metabolic phenotype. It should be noted that the relationship between the tumor 
microenvironment and cancer cell metabolism is not one of simple cause and effect, in 
which biochemical conditions in the tumor influence cellular metabolism. Because 
metabolite concentrations are governed by both supply by the vasculature and demand 
by the tissue, changes in metabolism of both the tumor and normal stromal cells also 
have a profound effect on microenvironmental conditions (Cairns et al., 2011). 
1.3.  Mitochondria and cancer 
Many vital cellular parameters are controlled by mitochondria. These include regulation 
of energy production, modulation of oxidation-reduction (redox) status, generation of 
reactive oxygen species (ROS), control of cytosolic Ca2+ levels, contribution to cytosolic 
biosynthetic precursors such as acetyl-CoA and pyrimidines, and initiation of apoptosis 
and necrosis through the activation of the mitochondrial permeability transition pore 
(mtPTP) and the release of apoptogenic proteins (Tait and Green, 2010). Changes in these 
parameters can impinge on biosynthetic pathways, cellular signal transduction pathways, 
transcription factors and chromatin structure to shift the cell from a quiescent, 
differentiated state to an actively proliferating one (Wallace, 2012). 
Although mutations in the mitochondrial DNA (mtDNA) of cancer cells have been 
recognized for more than two decades (Horton et al., 1996), the role of mitochondrial 
alterations in cancer came to general attention only in 2000, with the discovery that 
mutations in the TCA cycle genes succinate dehydrogenase (SDH) (Baysal et al., 2000) and 
fumarate hydratase (FH) (Tomlinson et al., 2002) are causative of specific tumor subsets. 
More recently it was found that also mutations in isocitrate dehydrogenase 1 (IDH1) and 
IDH2 are tumorigenic (Fig. 11) (Ward et al., 2010). 
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Figure 11. Mitochondrial bioenergetics and cancer cell mutations. Pyruvate dehydrogenase (PDH) can be inactivated 
through phosphorylation by PDH kinase (PDHK) and reactivated through dephosphorylation by PDH phosphatase 
(PDHP). Cancer mutations have been identified in IDH2, SDH, and FH (shown as red ovals). FH defects are associated 
with induction of the haemoxygenase 1 (HMOX1), which degrades haem. Cancer cell mitochondrial DNA (mtDNA) 
mutations have been reported in genes for complexes I, III, IV and V (shown as red squares). Hence, many of the 
mitochondrial gene mutations in cancer are intimately associated with OXPHOS and the redox regulation of reactive 
oxygen species (ROS) (Wallace, 2012). 
1.3.1. Mutations that affect mtDNA 
Contrary to conventional wisdom, functional mitochondria are essential for the cancer 
cell. Although mutations in mitochondrial genes are common in cancer cells, they do not 
inactivate mitochondrial energy metabolism but rather alter the mitochondrial 
bioenergetic and biosynthetic state. 
1.3.1.1. ρ0 cells and tumorigenesis 
The requirement of cancer cells for functional mitochondria has been confirmed by the 
elimination of mtDNA from various cancer cells through growth in ethidium bromide (ρ0 
cells) (King and Attardi, 1996). The resulting ρ0 cancer cells have reduced growth rates, 
decreased colony formation in soft agar and markedly reduced tumor formation in nude 
mice (Wallace, 2012). However, this model of mitochondrial dysfunction has been widely 
controversial given the extreme mitochondrial damage: ρ0 cells do not show any 
mitochondrial respiration and fully depend on glycolysis for energy demands. Thus, these 
cells have been used as a model both for mitochondrial dysfunction pathologies and 
tumors, as they implement bioenergetic adjustments which are often shared by the two 
groups of diseases. 
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1.3.1.2. mtDNA mutations and cancer 
Since mtDNA is in the proximity of ROS generation sites (the byproduct of OXPHOS) and 
mitochondria have relatively less sophisticated DNA protection or repair systems, mtDNA 
is vulnerable to high mutation rates. As a result, the mtDNA within a cell could be a blend 
of both wild-type and mutant species, a condition called ‘heteroplasmy’. The normal 
situation, in which all mtDNAs are identical, is referred to as ‘homoplasmy’. The neutral 
polymorphisms are most likely homoplasmic, whereas the pathogenic mutations are 
usually heteroplasmic in nature. It is expected that, due to the multiplicity of 
mitochondrial genomes in each cell, a threshold of mutant mtDNA must be reached 
before it can induce a cellular dysfunction, and a further threshold of dysfunctional cells 
within a tissue must be reached before such a defect becomes apparent.  
Somatic and germline mtDNA mutations have been reported for a wide variety of 
cancers. These include renal adenocarcinoma, colon cancer cells, head and neck tumors, 
astrocytic tumors, thyroid tumors, breast tumors, ovarian tumors, prostate and bladder 
cancer, neuroblastomas and oncocytomas. Ancient mtDNA population variants have also 
been correlated with cancer risk. For example, the macrohaplogroup N variant in the 
complex I, subunit ND3 gene (ND3; also known as MTND3) at nucleotide G10398A 
(resulting in a T114A amino acid change) has been associated with breast cancer risk in 
African American women, and the 16519 T to C mtDNA control region variant is 
associated with endometrial cancer (Wallace, 2012). 
A meta-analysis of many cancer-associated mtDNA mutations revealed that many cancer 
cell mtDNA mutations clearly inhibit OXPHOS. However, a significant proportion of the 
reported variants are the same nucleotide changes that have previously been reported as 
ancient adaptive mtDNA variants in human populations. Although some of these cancer 
‘associations’ are clear misinterpretations of ancient polymorphisms, others may be valid 
cancer cell mutations. However, it must be highlighted that in principle two classes of 
mutations may affect mtDNA of cancer cells: mutations that stimulate neoplastic 
transformation, e.g. by facilitating cancer cell adaption to a changing bioenergetic 
environment through OXPHOS impairment, and those that are a by-product of primary 
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tumorigenic alterations, such as dysregulation of redox equilibrium, and that could 
further enhance cell malignancy (Brandon et al., 2006). 
Intriguingly, the extent of mtDNA heteroplasmy versus homoplasmy appears to affect 
oxyradical formation and tumorigenicity. At heteroplasmic levels, a mutation in MT‑ND5 
is associated with increased generation of oxyradicals and tumorigenicity, whereas 
homoplasmic MT‑ND5 mutations appear to exhibit decreased oxyradical formation and 
tumorigenicity. Thus, a dosage effect of mtDNA mutations may determine the extent of 
redox stress and tumorigenicity (Koppenol et al., 2011). 
1.3.2. Defects of mitochondrial enzymes in cancer 
Over the past two decades, the discovery of oncogenes and tumor suppressor genes has 
created a paradigm by which cell-autonomous genetic alterations were considered the 
main driving force for neoplastic transformation through dysregulation of a small set of 
crucial biological processes (Hanahan and Weinberg, 2000), whereas alterations of cell 
metabolism were considered as epiphenomena of the tumorigenic process. However, 
with the discoveries of oncogenic mutations affecting mitochondrial metabolic enzymes, 
it is now untenable to deny the role of metabolism in tumorigenesis. Indeed, signaling 
mediated by metabolites, e.g. succinate and fumarate, or other mitochondria-derived 
molecules has been suggested to trigger oncogenic transformation, thus establishing a 
new paradigm in oncogenesis: a mutation can drive neoplastic transformation by inducing 
the accumulation of a molecule called ‘oncometabolite’. 
1.3.2.1. Succinate dehydrogenase mutations 
SDH is a tetrameric enzyme placed at the crossroad between the TCA cycle and the 
electron transport chain (ETC), of which it is an integral part (respiratory chain complex 
II). Germline mutations in all the genes encoding the subunits of SDH predispose 
individuals to hereditary paraganglioma and phaeochromocytoma, inherited tumor 
susceptibility syndromes (Bardella et al., 2011; Baysal et al., 2000). It was then 
demonstrated that impaired HIFα degradation due to the inhibition of its hydroxylation 
by PHDs is at the heart of the pathology of these tumors (Briere et al., 2005; Pollard et al., 
2005; Selak et al., 2005). Two models that explain anomalous HIFα stabilization under 
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normoxia due to SDH mutations have been proposed (Fig. 12). The first suggested that 
ROS, generated from an impaired complex II, oxidate iron and ascorbate, that are 
cofactors of PHDs, preventing HIFα hydroxylation by inhibiting PHDs. However, there are 
conflicting data as to ROS production in SDH deficient cells (Ishii et al., 2005; Selak et al., 
2005). This controversy may be attributed to the mechanism used for SDH inactivation 
(mutations versus siRNAs) or to the methods used for ROS analysis. The second model 
demonstrated that succinate, which builds up in SDH-deficient mitochondria, can serve as 
a mitochondria-to-cytosol messenger that inhibits PHD activity (Selak et al., 2005). The 
stabilized HIF1α is then translocated into the nucleus and causes a shift from oxidative to 
glycolytic energy metabolism. 
 
Figure 12. The physiological roles of SDH in the TCA cycle and the ETC and its potential roles in cancer. (A) Ribbon 
diagram of SDH structure. The catalytic subunits, i.e. the flavoprotein (SDHA) and the iron-sulphur protein (SDHB) are 
depicted in red and yellow, respectively, and the membrane anchor and ubiquinone binding proteins SDHC and SDHD 
are depicted in cyan and green, respectively. (B) Other than being a TCA enzyme, SDH is an additional entry point to the 
ETC. The electron flow in and out of complex II and III is depicted by the yellow arrows. Complex III is the best 
characterized site of ROS production in the ETC, where a single electron reduction of oxygen to superoxide can occur 
(red arrow). It was proposed that obstructing electron flow within complex II might support a single electron reduction 
of oxygen at the FAD site (red arrow). Superoxide is dismutated to hydrogen peroxide which can then leave the 
mitochondria and inhibit PHD in the cytosol, leading to HIFα stabilization. Succinate or fumarate, which accumulates in 
SDH- or FH-deficient tumors, can also leave the mitochondria and inhibit PHD activity in the cytosol. The red dotted line 
represents the outer mitochondrial membrane (OMM) (Frezza and Gottlieb, 2009). 
1.3.2.2. Fumarate hydratase mutations 
Homozygous null mutations in the FH gene are associated with multiple cutaneous and 
uterine leiomyomatas and aggressive forms of renal cell cancer (Tomlinson et al., 2002). 
FH converts fumarate to malate, and cells harboring FH mutations produce up to 100‑
fold more fumarate, sevenfold more succinate, and have a marked decrease in malate 
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and citrate levels. Fumarate has also been hypothesized to inhibit PHDs and stabilize 
HIF1α, even though this observation is still a matter of debate (Adam et al., 2011). 
Increased fumarate levels have been found to activate the stress response pathway that 
is regulated by NFE2‑related factor 2 (NRF2; also known as NFE2L2). NRF2 is normally 
kept at low levels through degradation by the kelch-like ECH-associated protein 1 (KEAP1) 
and the ubiquitin E3 ligase cullin 3 complex. However, excess fumarate can inactivate 
KEAP1 through succination of cysteines 151 and 288, thereby stabilizing NRF2. NRF2 binds 
to the antioxidant response elements (AREs) and turns on DNA stress-response genes, 
one of which is haem oxygenase 1 (HMOX1). The induction of HMOX1 is important to 
tumorigenesis because silencing or inhibiting HMOX1 in FH knock out cells reduces 
colony-forming capacity (Frezza et al., 2011). Inactivation of FH would not only increase 
fumarate and succinate levels but would also increase succinyl-CoA levels. The induction 
of HMOX1 could reduce the levels of these metabolites as haem biosynthesis involves 
combining succinyl-CoA with glycine to generate δ‑aminolevulinic acid (ALA) by ALA 
synthetase (ALAS) to initiate porphyrin synthesis. Porphyrins are converted to haem, 
which is degraded by HMOX1 to result in the production and excretion of bilirubin (Fig. 
11). This raises the question of why might it be beneficial for the malignant cell to reduce 
succinyl-CoA levels. One possibility could be that when succinyl-CoA is converted to 
succinate by succinyl-CoA synthetase, GTP is generated. GTP hydrolysis is in turn coupled 
to the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) by mitochondrial 
PEP carboxykinase (PEPCK‑M), and mitochondrial PEP is exported to the cytosol where it 
can be converted to pyruvate and ATP. If succinyl-CoA were in excess, this reaction could 
deplete the mitochondrion of OAA that is required for citrate synthesis and lipid 
biogenesis. Moreover, excess GTP might adversely affect the homeostasis of the 
mitochondrial nucleotide pool and compromise mtDNA transcription and replication 
(Wallace, 2012). 
1.3.2.3. Isocitrate dehydrogenases 
Heterozygous missense mutations in the two NADP+-dependent IDH enzymes, cytosolic 
IDH1 and mitochondrial IDH2, have been observed in low-grade gliomas and secondary 
glioblastomas, astrocytomas, chondromas and acute myeloid leukaemia (AML) (Schaap et 
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al., 2013). A third IDH, NAD+-dependent IDH3, is the primary TCA cycle enzyme for 
decarboxylating isocitrate to α‑ketoglutarate (Fig. 11), yet this enzyme has not been 
found to be mutated in cancer. Like IDH3, IDH1 and IDH2 can oxidatively decarboxylate 
isocitrate to α‑ketoglutarate. However, IDH1 and IDH2 reduce NADP+ instead of NAD+, 
and the NADP+-dependent reaction is reversible because NADPH can provide sufficient 
energy to drive the reductive carboxylation of α‑ketoglutarate to isocitrate. 
 
Figure 13. IDH1 and IDH2 mutations cause an oncometabolic gain of function. Instead of isocitrate being converted to 
α-ketoglutarate (αKG) with the production of reduced nicotinamide adenine dinucleotide phosphate (NADPH), αKG is 
converted to 2-hydroxyglutarate (2-HG) with the consumption of NADPH (Cairns et al., 2011). 
The IDH1 and IDH2 mutations associated with the development of glioma and AML are 
restricted to crucial arginine residues required for isocitrate binding in the active site of 
the protein: R132 in IDH1, and R172 and R140 in IDH2 (Ward et al., 2010). Affected 
patients are heterozygous for these mutations, suggesting that these alterations may 
cause an oncogenic gain-of-function. It was initially proposed that these mutations might 
act through dominant-negative inhibition of IDH1 and IDH2 activity, which could lead to a 
reduction in cytoplasmic αKG concentration, inhibition of prolyl hydroxylase activity and 
stabilization of HIF1. However, it has recently been shown that these mutations cause 
IDH1 and IDH2 to acquire a novel enzymatic activity that converts αKG to 2-
hydroxyglutarate (2-HG) in a NADPH-dependent manner (Dang et al., 2009). In fact, this 
change causes the mutated IDH1 and IDH2 enzymes to switch from NADPH production to 
NADPH consumption, with potentially important consequences for the cellular redox 
balance (Fig. 13). Indeed, the resulting decrease in NADPH levels would inhibit 
glutathione peroxidase, thus increasing H2O2 levels with heightened signaling effects. 
Moreover, decreased NADPH production would also inhibit the thioredoxins and the 
bifunctional apurinic/apyrimidinic endonuclease 1 (APE1; also known as redox factor 1 
29 
 
(REF1)), thus perturbing the redox status of crucial transcription factors and favoring 
proliferation and tumorigenesis (Wallace, 2012). 
The product of the novel reaction, 2-HG, is a poorly understood metabolite and it remains 
to be determined whether the high concentrations of 2-HG are mechanistically 
responsible for the ability of IDH1 and IDH2 mutations to drive tumorigenesis. 2-HG is 
associated with alterations in cellular genomic methylation and transcription patterns and 
is a potent inhibitor of the αKG-dependent dioxygenases, particularly of the Jumonji C 
domain–containing histone lysine demethylases (KDMs) and the ten eleven translocation 
(TET) family of 5-methylcytosine (5mC) hydroxylases, which results in epigenetic 
alterations that affect the expression of genes involved in cell differentiation and the 
acquisition of malignant features. Furthermore, 2-HG inhibits collagen prolyl and lysyl 
hydroxylases (C-P4Hs and PLODs, respectively), leading to impaired collagen maturation 
and disrupted basement membrane formation, and stimulates PHDs activity, leading to 
enhanced HIF degradation and a diminished HIF response (Yang et al., 2013). Together 
these processes exert pleiotrophic effects on cell signaling and gene expression that 
probably contribute to the malignancy of IDH1/2-mutant cells. 
Importantly, levels of αKG, isocitrate and several other TCA metabolites are not altered in 
cell lines or tissues expressing IDH1 mutations, suggesting that other metabolic pathways 
can adjust and maintain normal levels of these essential metabolites. Curiously, although 
IDH1 and IDH2 mutations are clearly powerful drivers of glioma and AML, they seem to be 
rare or absent in other tumor types. This observation highlights the importance of the 
specific cellular context in understanding metabolic perturbations in cancer cells. 
1.3.3. OXPHOS assembly and regulation 
Respiration can also be down-modulated through inhibition of the functional assembly of 
respiratory chain complexes. A recent model proposes that respiratory complexes are 
organized in functional super-complexes, for example aggregates of Complex I-III-IV in 
different stoichiometries, which form the so-called ‘respirasome’ (Acin-Perez et al., 
2008). The correct supra-complex assembly would be a crucial regulatory event in 
obtaining a fully functional respiratory chain. Recent reports have shown that OXPHOS 
impairment in cancer cells can be due to a dysregulation in the assembly of these super-
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complexes, whose disassembly could favor the switch towards glucose metabolism 
(Baracca et al., 2010). It has been proposed that a combination of genetic (low 
transcription of some genes) and biochemical events (assembly factors deficiency, 
disorganization of structured super-complexes, and ROS-induced structural damage) 
might cause OXPHOS defects. For instance, a reduction of Complex I activity relative to 
other respiratory chain complexes is recurrent in a number of cancer cells of different 
origin. Significantly, all these tumor cells are characterized by an overproduction of ROS 
which is consistent with the hypothesis that Complex I-III super-complex formation allows 
electrons channeling, therefore preventing ROS production. If an altered Complex I 
cannot associate with Complex III in super-complexes, electrons are not correctly 
funneled from NADH through coenzyme Q to Complex III redox centers, determining ROS 
overproduction. This, in turn, enhances respiratory chain complex alteration resulting in 
further ROS production, thus establishing a vicious cycle of oxidative stress and energy 
depletion. These alterations could further damage cell structures and dysregulated key 
transduction pathways, with consequent tumor progression and metastasis (Solaini et al., 
2011). 
 
Figure 14. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. 
TRAP1 binds to and inhibits the enzymatic activity of CII leading to an increase in succinate level; this is responsible for 
PHD inhibition which results in HIF1α stabilization and neoplastic growth (Sciacovelli et al., 2013).  
Given the importance of succinate levels in HIF1α stabilization, it is useful to highlight that 
Complex II (CII) is also a target of important regulation in tumors. A recent work from our 
laboratory showed that CII is bound and inhibited by a mitochondrial chaperone, called 
TRAP1, which is often up-regulated in cancer (Sciacovelli et al., 2013). TRAP1-expressing 
cells display a decrease in mitochondrial respiration and reorient their metabolism 
toward glycolysis to meet their energy demand. Despite normoxic conditions, HIF1α is 
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exclusively induced in TRAP1-expressing cells through the increase in succinate levels (Fig. 
14); in turn, HIF1α is required for TRAP1-induced oncogenic transformation. These 
findings potentially have a very high impact, as targeting this oncogenic metabolic activity 
of TRAP1 may be an effective anti-neoplastic strategy. 
1.3.4. Mitochondrial retrograde signaling 
The discovery of oncometabolites points out the ability of mitochondria to communicate 
with the other components of the cell in order to coordinate a variety of cellular functions 
in an integrated way. The role of the nucleus in regulating mitochondrial function has 
been examined extensively but the importance of mitochondrial events in signaling to the 
nucleus, the so called mitochondrial ‘retrograde signaling’, and to other cell growth 
mechanisms, has been relatively under-studied.  
 
Figure 15. Retrograde signaling from mitochondria to nucleus and cytoplasm. (A) Mitochondrial control of nuclear 
gene expression through effects of altered production of certain metabolites, such as α-ketoglutarate and succinate, on 
epigenetic modification of histones, stabilization of key transcription factors, such as HIF, in addition to effects on other 
enzymes and proteins. (B) Altered production of NAD
+
, ATP, and other changes in mitochondrial metabolism can 
modulate key signaling molecules in the cell, such as AMPK and the Sirtuins. (C) Mitochondria play a key role in 
buffering against Ca
2+
 flux into the cytosol from the extra-cellular environment or following release from the ER. Altered 
Ca
2+
 signaling in the cell has a strong impact on the activation of different cellular signaling cascades. (D) Mitochondrial 
ROS production has been one of the most extensively studied mediators of mitochondrial dysfunction and activity that 
elicits its effects on transcription factor activity as well as activity of key enzymes in the cell, such as caspases and 
phosphatases. (E) Important cellular kinases are known to localize to the mitochondria and altered mitochondrial 
dynamics and function may modulate the activity of these kinases not just at the mitochondria but at other sub-cellular 
locations if released from the mitochondria (Boland et al., 2013). 
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Key aspects of cellular function are influenced by signaling molecules produced and 
released by mitochondria as part of their normal metabolism (Fig. 15). As a consequence, 
altered mitochondrial physiology of cancer cells significantly reprograms the nucleus and 
impacts on cytoplasmic signaling pathways in ways that are important for neoplastic 
transformation. 
It has been proposed that mitochondria and the nucleus cooperate to shape the 
oncogenic signaling cascade, leading to the reconciliation between the classic “gene-
centric” view of cancer and the Warburg hypothesis (Frezza, 2014). Several components 
of the oncogenic signaling cascade affect mitochondrial function by keeping in check 
apoptosis and controlling mitochondrial metabolism. Although these functions are critical 
for shaping the cellular response to an oncogenic signal, mitochondria further integrate 
the signaling cascade by communicating back to the nucleus that undergoes further 
genetic reprogramming (Fig. 16). Events that alter any of these steps in intracellular 
communication contribute to the cell fate decision. 
 
Figure 16. Mitochondria and the nucleus cooperate to shape the oncogenic signaling cascade. The classic ‘gene-
centric’ view of cancer (green arrows) and the Warburg hypothesis (red arrows) are represented. The activation of an 
oncogenic signaling cascade results in the genetic reprogramming of the cells. At the same time, components of the 
activated signaling cascade alter mitochondrial function which, in turn, triggers a retrograde signaling response (blue 
arrows) that shape nuclear gene expression and the signaling cascade itself. Importantly, in some circumstances, 
mitochondrial dysfunction is sufficient to initiate tumorigenesis, suggesting that alterations to any of the indicated 
components (signal transduction, mitochondria and nucleus) are sufficient to predispose to tumorigenesis (Frezza, 
2014). 
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1.3.5. Mitochondria as cell death modulators 
The cell death machinery can be broadly divided into three classes of components — 
sensors, integrators (e.g. Bcl-2 family proteins) and effectors. The sensors are responsible 
for monitoring the extracellular and intracellular environment for conditions that 
influence whether a cell should live or die. These signals regulate the second class of 
components, which function as effectors of cell death. The sentinels include cell surface 
receptors that bind survival or death factors. Intracellular sensors monitor the cell’s well-
being and activate the death pathway in response to a variety of stress stimuli, including 
DNA damage, signaling imbalance provoked by oncogene action, survival factor 
insufficiency, or hypoxia. Further, the life of most cells is in part maintained by cell-matrix 
and cell-cell survival signals, whose abrogation elicits apoptosis (Hanahan and Weinberg, 
2000).  
Mitochondria are the cells’ powerhouse, but also their suicidal powder keg. Dozens of 
lethal signal transduction pathways converge on mitochondria to cause the 
permeabilization of the mitochondrial outer membrane, leading to the cytosolic release 
of pro-apoptotic proteins and to the impairment of the bioenergetic functions of 
mitochondria (Fig. 17). 
34 
 
 
Figure 17. Intrinsic and extrinsic pathways of apoptosis. a) Intrinsic apoptotic stimuli, such as DNA damage or 
endoplasmic reticulum (ER) stress, activate BH3-only proteins leading to BAX and BAK activation and mitochondrial 
outer membrane permeabilization (MOMP). Anti-apoptotic BCL-2 proteins prevent MOMP by binding BH3-only proteins 
and activated BAX or BAK. Following MOMP, release of various proteins from the mitochondrial intermembrane space 
(IMS) promotes caspase activation and apoptosis. Cytochrome c binds apoptotic protease-activating factor 1 (APAF1), 
inducing its oligomerization and thereby forming a structure termed the ‘apoptosome’ that recruits and activates an 
initiator caspase, caspase-9. Caspase-9 cleaves and activates executioner caspases, caspase-3 and caspase-7, leading to 
apoptosis. Mitochondrial release of second mitochondria-derived activator of caspase (SMAC; also known as DIABLO) 
and OMI (also known as HTRA2) neutralizes the caspase inhibitory function of X-linked inhibitor of apoptosis protein 
(XIAP). b) The extrinsic apoptotic pathway is initiated by the binding of death receptors by their cognate ligands, leading 
to the recruitment of adaptor molecules such as FAS-associated death domain protein (FADD) and then caspase-8. This 
results in the dimerization and activation of caspase-8, which can then directly cleave and activate caspase-3 and 
caspase-7, leading to apoptosis. Crosstalk between the extrinsic and intrinsic pathways occurs through caspase-8 
cleavage and activation of the BH3-only protein BID, the product of which (truncated BID; tBID) is required in some cell 
types for death receptor-induced apoptosis. FASL, FAS ligand; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-
inducing ligand (Tait and Green, 2010). 
Moreover, opening of high conductance channels in mitochondria initiates the 
mitochondrial permeability transition (MPT). MPT is a universal feature of cell death and 
is often considered as the ‘point of no return’ in the cascade of events leading to cell 
death. The mechanisms underlying MPT are complex and reflect the key role played by 
mitochondria in integrating numerous endogenous and exogenous signals (e.g., cytosolic 
and organellar concentrations of protons, Ca2+, Mg2+, K+, and Na+, metabolites such as 
ATP, ADP, NAD(P), glutathione, lipid second messengers, and multiple proteins including 
kinases and phosphatases) (Ulivieri, 2010). 
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1.3.5.1. The permeability transition pore (PTP) 
The mitochondrial permeability transition is an increase of mitochondrial inner 
membrane permeability to solutes with molecular masses up to 1500 Da. Under the 
conditions used in most in vitro studies, MPT is accompanied by depolarization, Ca2+ 
release into the cytosol, matrix swelling with inner membrane remodeling, depletion of 
matrix pyridine nucleotides, cessation of OXPHOS, outer membrane rupture and release 
of intermembrane apoptogenic proteins, including cytochrome c. The occurrence of 
swelling in isolated mitochondria, its stimulation by Ca2+, phosphate (Pi) and fatty acids, 
its inhibition by Mg2+, adenine nucleotides and acidic pH, and its detrimental effects on 
energy conservation, have been clearly recognized since the early studies on isolated 
mitochondria were carried out (Bernardi et al., 2006).  
The MPT is caused by the opening of a large Ca2+- and oxidative stress-activated pore, 
named Permeability Transition Pore (PTP), whose molecular nature is being finally 
delineated: the dimeric form of ATP synthase and CyP-D as regulator are currently 
proposed as components (Fig. 18) (Giorgio et al., 2013). Therefore, the key enzyme of life 
appears to be also the molecular switch that signals the presence of fully depolarized, 
dysfunctional mitochondria to promote cell death (Bernardi, 2013). 
  
Figure 18. Hypothetical transition of FOF1 ATP synthase dimers to form the PTP. ATP synthase dimers (A) can undergo 
PTP formation when Ca
2+
 rather than Mg
2+
 is bound, possibly at the catalytic sites, in a reversible process favored by 
thiol oxidation (C). Binding of CyPD, which is favored by Pi (B) would increase the accessibility of the metal binding sites, 
allowing PTP formation at lower Ca
2+
 concentrations (as depicted here by a smaller face type) (D). Adenine nucleotides 
counteract PTP formation in synergy with Mg
2+
. Red arrows denote the hypothetical pathway for solute diffusion 
between two FO subunits (Bernardi, 2013). 
Enhanced or inhibited MPT has been described as a feature of many human diseases such 
as ischemia/reperfusion, intoxication with xenobiotics, viral infections, 
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neurodegeneration, muscular dystrophy caused by collagen VI deficiency, cancer and 
many others. These diseases are favored by altered exogenous conditions (e.g., lack of 
oxygen, xenobiotic accumulation, pathogen infection, oxidative stress) or by mutations 
affecting endogenous effectors (e.g., huntingtin in Huntington disease) (Rasola and 
Bernardi, 2007). 
1.3.5.2. Death resistance of cancer cells 
Tumor cells evolve a variety of strategies to limit or circumvent apoptosis. Most common 
is the loss of TP53 tumor suppressor function, which eliminates this critical damage 
sensor from the apoptosis-inducing circuitry. Alternatively, tumors may achieve similar 
ends by increasing expression or function of anti-apoptotic regulators (Bcl-2, Bcl-XL) or of 
survival signals (growth factors, receptor tyrosine kinases), by down-regulating pro-
apoptotic factors (Bax, Bim, Puma), or by short-circuiting the extrinsic ligand-induced 
death pathway. The multiplicity of apoptosis-avoiding mechanisms presumably reflects 
the diversity of apoptosis-inducing signals that cancer cell populations encounter during 
their evolution to the malignant state. 
Apart from dysregulation in the pathways that sense apoptotic or survival stimuli, tumor 
cells can also modify key steps of the death execution process. Given that one of the 
decisive events toward cell demise is the increase of mitochondrial inner membrane 
permeability, cancer cells often manifest resistance against mitochondrial membrane 
permeabilization (Rasola and Bernardi, 2007). 
Several independent mechanisms may inhibit mitochondrial permeabilization, and MPT is 
a key target for these regulatory devices. On theoretical grounds, these include the 
following: 1) alterations (e.g., up-regulation, repression) of gene expression level, 
resulting from genetic (e.g., amplification) or epigenetic (e.g., aberrant methylation) 
events; 2) loss-of-function mutations; or 3) defects in the post-translational regulation, 
resulting in changes of protein activity or intracellular localization/trafficking (e.g., 
inhibition of Bax translocation to mitochondria). All these aberrations may concern 
structural PTP proteins as well as MPT regulators. Altered signal transduction pathways 
leading to the inhibition of MPT will be discussed in the next section. 
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1.4.  Signaling toward mitochondria 
All eukaryotic cells coordinate their growth with the availability of nutrients in their 
environment. Signal transduction is the process by which environmental stimuli are 
conveyed inside a cell to induce a biological response: a ligand activates a cognate 
receptor that in turn prompts a chain of alterations in intracellular proteins to create a 
response. Signaling cascades directly regulate protein synthesis, cell growth and 
proliferation, metabolism, apoptosis and motility, and orchestrate post-translational 
modifications of proteins, mainly reversible phosphorylations, which lead to changes in 
interactions or subcellular localization of proteins, or to modulation of transcription. 
Therefore, deregulation of signal transduction pathways in tumors alters fundamental 
biological processes, disturbing tissue homeostasis and causing a concomitant net 
increase in cell number. Constitutive dysregulation of diverse transduction pathways may 
confer treatment resistance, since the response of cancer cells towards most cytotoxic 
therapies including chemo-, radio- or immunotherapy critically depends on intact 
signaling cascades that eventually lead to cell death. Hence, a better understanding of the 
molecular mechanisms that regulate cell death and survival programs in cancer cells is 
expected to provide the basis for the development of new and selective therapeutic 
strategies. 
Three decades of molecular oncology have revealed that virtually every type of cancer cell 
displays mutations in components of the molecular pathways that transduce growth 
factor-derived signals. The main classes of signaling molecules that are disrupted in 
cancer are: 
- Growth Factor receptors; 
- GTPases; 
- Cytosolic Serine/Threonine or Tyrosine Kinases; 
- Phosphatases; 
- Adaptor, chaperone and scaffold proteins. 
Notably, these proteins form biochemical axes that intersect in complex networks; as a 
consequence, each mutation has multiple effects that impact on cell growth, 
proliferation, motility and survival, rendering each of these processes unrestricted by 
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environmental cues (Shaw and Cantley, 2006). Moreover, even if components of these 
signaling cascades are attractive targets for selective therapeutic interventions (Knight et 
al., 2010; Zhang et al., 2009), the presence of redundant circuitries can create problems of 
efficacy, as tumor cells can bypass the signaling cascade blocked by a specific drug; and 
the physiological functions of these same proteins in non-malignant cells raises important 
selectivity issues. 
Several signaling pathways have been shown to also possess a mitochondrial branch, and 
both kinases and phosphatases have been found inside mitochondria. This research field 
is relatively new and displays numerous difficulties, first of all the absence of recognized 
mitochondrial import sequences in many of the cytosolic or nuclear proteins that have 
also been detected in mitochondria. Nonetheless, it is emerging that some crucial 
biological processes that occur into mitochondria can be modulated by reversible 
phosphorylation, under the tight control of transduction axes that originate outside the 
organelle. The section below illustrates how a network of phosphorylation events might 
control PTP by modulating the activity and localization of mitochondrial kinases and 
chaperones. These observations suggest that the mitochondrial pore could constitute an 
important downstream effector of kinase signaling pathways; in tumor cells, 
dysregulation of these pathways would inhibit PTP opening, contributing to the 
phenotype of cell death inhibition that characterizes neoplasms. Thus, components of 
mitochondrial signaling are attractive targets for anti-neoplastic strategies. 
1.4.1. Hexokinase II (HK II) 
An example of the interplay between mitochondria and cytosolic signal transduction is 
hexokinase (HK), an enzyme that initiates all major pathways of intracellular glucose 
utilization; interestingly, type II HK (HK II) couples glycolysis to OXPHOS by interacting 
with mitochondria, thus acting as a metabolic sensor. In highly glycolytic and extremely 
aggressive tumors, mitochondrial HK II activity is increased and fosters cell growth in 
hypoxic conditions by enhancing glycolysis, which becomes independent of oxygen 
availability. Furthermore, mitochondrial HK II plays an important role in maintaining the 
integrity of the outer mitochondrial membrane (OMM); indeed, HK II interacts with the 
voltage-dependent anion channel (VDAC), a protein that allows for the movement of 
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small metabolites across the OMM. This interaction not only facilitates glucose 
phosphorylation but also keeps VDAC in the open state, which counteracts OMM 
permeabilization. Furthermore, HK II occupies binding sites for pro-apoptotic proteins on 
the OMM thus preventing the release of key apoptogenic molecules from the 
intermembrane space (Mathupala et al., 2006). 
 
Figure 19. PTP regulation by mitochondrial hexokinase (HK). (A) Akt activation by receptor tyrosine kinases (RTKs) or 
during neoplastic transformation keeps HK bound to the mitochondrial surface, both through a direct HK 
phosphorylation and through an inactivating serine phosphorylation of GSK3β. Inactive GSK3β cannot phosphorylate 
VDAC, favoring its binding to HK and to anti-apoptotic Bcl-2 family proteins, and displacing the binding of pro-apoptotic 
Bax/Bak. However, VDAC is dispensable for HK interaction with mitochondria, suggesting that (an) unknown partner(s) 
is/are involved in this process. HK utilizes the ATP synthesized by mitochondria to start glucose metabolism, and 
stabilizes the PTP in a closed state. (B) Either Akt inactivation or treatment with a HK peptide induces HK detachment 
from the outer mitochondrial membrane, possibly leading to conformational changes of ANT and CyP-D and eventually 
to PTP opening and cell death. GSK3β is activated by Akt inhibition. The ensuing VDAC phosphorylation leads to Bcl-2/XL 
displacement and favors Bax/Bak activation, but PTP opening induced by HK detachment from mitochondria does not 
require VDAC (Rasola et al., 2010). 
Notably, signal transduction pathways converge on mitochondrial HK II (Fig. 19). This is of 
pivotal importance in cancer, because tumor cells are endowed with hyper-activation of 
these same anabolic transduction pathways. The survival kinase Akt, which is activated by 
growth factors and is hyper-active in many tumor types, promotes HK II binding to 
mitochondria by phosphorylating both HK II itself and glycogen synthase kinase 3β 
(GSK3β), a kinase which is inhibited by this phosphorylation. Akt-dependent 
phosphorylation of mitochondrial HK II inhibits Ca2+-induced cytochrome c release, and 
association of HK II to the OMM is favored when GSK3β is inactivated by Akt 
phosphorylation (Rasola et al., 2010).  
Accordingly, activation of GSK3β was shown to induce release of HK II, enhancing 
susceptibility to cell death. This was proposed to require GSK3β phosphorylation of 
putative HK docking site on VDAC, which would displace Bcl-2 from its interaction with 
VDAC, favoring the binding between VDAC and the pro-apoptotic Bax/Bak proteins in 
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conditions of growth factor deprivation, resulting in increased sensitivity of mitochondria 
to PTP induction. However, the physiological role of GSK3-mediated phosphorylation of 
VDAC is unknown, as mitochondrial displacement of HK II elicits cell death also in 
conditions of GSK3 inhibition, in cells lacking any detectable binding between HK II and 
VDAC (Chiara et al., 2008), and in the absence of Bax and Bak (Majewski et al., 2004). 
1.4.2. Glycogen synthase kinase 3 (GSK3) 
GSK3 is a Ser/Thr protein kinase ubiquitously expressed which, at variance from the 
majority of kinases, is constitutively active; more than 50 substrates of GSK3 have been 
identified. Dysregulation of GSK3 is linked to a large number of prevalent diseases 
including psychiatric disorders, neurodegenerative diseases, ischemia/reperfusion injury, 
diabetes, and cancer. In tumors, multiple transduction pathways that are constitutively 
activated converge on GSK3 to induce phosphorylation at Ser 9/21 residues, leading to 
inhibition of GSK3 enzymatic activity. GSK3 activity is inhibited both by growth factor 
signaling through the PI3K pathway or the MAPK cascade, and in response to agonists 
that activate protein kinase A (PKA) or protein kinase C (PKC). All these signals contribute 
to the oncogenic process by removing the tonic inhibitory effect exerted by GSK3 on a 
plethora of biochemical cascades (Jope and Johnson, 2004). 
 
Figure 20. Several kinase pathways converge on PTP regulation. A common target is GSK3β, which is inactivated by a 
group of survival kinases termed RISK (reperfusion injury salvage kinases) which includes the survival kinases Akt and 
Erk1/2, protein kinase Cε (PKCε), protein kinase G (PKG) and p70s6K. A small pool of GSK3β is in the mitochondrial 
matrix, where it favors PTP opening, possibly through CyP-D phosphorylation. In tumors, mitochondrial GSK3β is 
inactivated by ERK-dependent phosphorylation, raising the threshold for pore opening and therefore enhancing cell 
survival. GSK3β inactivation, and PKCε activity, could also contribute in keeping closed the PTP by opening 
mitochondrial KATP channels. CyP-D regulation of the pore is also influenced by the chaperones Hsp90 and TRAP1; 
TRAP1 is activated by the Ser/Thr kinase PINK1. Finally, PTP opening is inhibited by the phosphatase PP2Cm through 
unknown mechanisms. RTKs: receptor tyrosine kinases; GPCRs: G protein coupled receptors (Rasola et al., 2010). 
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As is the case for HK II localization on the OMM, in mitochondria GSK3 controls the 
localization and the activation status of a number of proteins of the cell death machinery. 
Beside this, it has been established that a fraction of GSK3 resides in mitochondria where 
it contributes to the regulation of energy metabolism and PTP opening (Chiara and 
Rasola, 2013). Indeed, it has been observed that cyclophilin D (CyP-D), a mitochondrial 
chaperone that regulates the PTP, is directly phosphorylated by GSK3 on Ser/Thr residues 
therefore sensitizing PTP to opening (Fig. 20). The mitochondrial fraction of GSK3 is in 
turn regulated by a portion of the kinase ERK, which also locates in the mitochondrial 
matrix in diverse neoplastic cell types. Mitochondrial ERK inhibits GSK3 by Ser 
phosphorylation, thus conferring resistance to death stimuli acting as PTP inducers. In 
accordance to this, ERK inhibition increases GSK3-dependent phosphorylation of CyP-D 
and sensitization of PTP to opening, thus significantly abolishing tumor cell protection 
from apoptosis, whereas pharmacological inhibition of GSK3 protects from PTP opening 
(Rasola et al., 2010). 
1.4.3. Extracellular signal regulated kinase (ERK) 
As we have illustrated above, a small portion of both ERK and GSK3 is located in the 
mitochondrial matrix in several neoplastic cell models, and both kinases directly interact 
with CyP-D. Mitochondrial ERK is constitutively active after v-Ki-Ras dependent 
transformation or in diverse tumor models, conferring resistance to death stimuli acting 
as PTP inducers (Rasola et al., 2010). This protection can be ablated by inhibiting ERK with 
the drug PD98059 or with a selective ERK activation inhibitor peptide. Notably, these 
treatments enhance GSK3-dependent phosphorylation of CyP-D and PTP opening, and the 
effect on the pore is increased after CyP-D overexpression and absent in CyP-D knock-out 
cells. Conversely, ERK activation prompts the inhibitory phosphorylation of GSK3 and 
abolishes CyP-D phosphorylation, therefore protecting from PTP opening. 
Thus, in diverse tumor cell models cell death susceptibility is modulated by the activity of 
mitochondrial ERK, which could directly impinge upon pore opening through the negative 
regulation of CyP-D phosphorylation by inhibiting the mitochondrial pool of GSK3. 
Mitochondria-specific ERK activation might provide a key advantage during neoplastic 
transformation, by placing the death/survival mitochondrial rheostat in an anti-apoptotic 
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mode, and it is highly probable that further mitochondrial targets of ERK could contribute 
to this process. To make this picture more complex, it must be highlighted that ERK is a 
GSK3 priming kinase, requiring the activity of a second kinase for complete GSK3 
inhibition, and that GSK3 itself needs a priming kinase to phosphorylate its targets. 
Moreover, these reactions must be finely tuned by the action of phosphatases (Rasola et 
al., 2010). 
1.4.4. Mitochondrial chaperones: CyP-D and TRAP1 
Molecular chaperones are involved in the correct folding of nascent polypeptides and in 
the productive assembly of multimeric protein complexes, while minimizing the danger of 
aggregation in the protein-rich intracellular environment. These proteins are also involved 
in the conformational changes associated to molecular dynamics, as in the case of 
propagation of signals through reversible phosphorylations, and in the regulation of 
protein degradation and turn-over (Akerfelt et al., 2010). Given the importance of these 
processes in protecting cells against harsh conditions (e.g., heat shock or oxidative stress) 
deregulation of chaperone activity could play a central role in different types of disease, 
among which cancer. Moreover, the localization of some chaperones is restricted to 
mitochondria suggesting the presence of mechanisms of control of protein activity which 
are organelle-specific. 
Cyclophilin D is a chaperone located in the mitochondrial matrix, endowed with a 
peptidyl-prolyl cis-trans isomerase activity. CyP-D is one of the best studied regulators of 
the PTP, and it sensitizes it to opening. However, the pore is still present in mitochondria 
and cells obtained from mice where the gene encoding CyP-D was knocked-out. CyP-D 
ablation increases the Ca2+ load required to open the PTP, unmasking inhibition by Pi, and 
abolishes sensitivity to the CyP-D ligand CsA, conclusively demonstrating that CyP-D is an 
important regulator of the PTP, but not a component of the channel (Baines et al., 2005; 
Basso et al., 2005). However, in some models CyP-D overexpression reportedly 
desensitizes cells from apoptosis (Schubert and Grimm, 2004) suggesting that CyP-D 
regulation of the PTP is not dictated only by the protein level but also by possible post-
translational modifications. We have previously described how its action can be 
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modulated by phosphorylations events (Fig. 20); moreover, it has been recently reported 
that CyP-D is also target of Sirtuin-3 deacetylation (Shulga et al., 2010).  
A chaperone homologous to heat shock protein 90 (Hsp90), termed tumor necrosis factor 
receptor-associated protein-1 (TRAP1), is highly expressed in mitochondria of tumor cells 
and of nervous tissue, whereas it is absent or expressed to a lower level in most normal 
tissues. Both TRAP1 and the mitochondrial fraction of Hsp90 interact with CyP-D and 
antagonize its function of PTP sensitization (Kang et al., 2007). TRAP1 knockdown 
enhances cell death, whereas TRAP1 overexpression confers resistance to pro-apoptotic 
drugs, suggesting that TRAP1 is a novel mitochondrial survival factor that acts as PTP 
inhibitor, and constitute a possible target of mitochondria-directed chemotherapeutics 
(Kang and Altieri, 2009). Importantly, TRAP1 was shown to be substrate of the Ser/Thr 
kinase PTEN induced kinase 1 (PINK1), and this phosphorylation was required to prevent 
oxidative-stress-induced apoptosis (Pridgeon et al., 2007). 
Altogether, these results further indicate that phosphorylation events can be crucial in 
the regulation of the PTP, and molecular chaperones as TRAP1 and CyP-D might be a link 
between kinase pathways and the pore. Furthermore, this could have important 
pathogenic implications, especially in tumors, where TRAP1 overexpression could 
substantially contribute to PTP desensitization to several insults. 
1.4.5. Neurofibromatosis type 1 
A group of tumors characterized by dysregulated signaling pathways which can also 
converge toward mitochondria are typical of a genetic disorder called Neurofibromatosis 
type 1 (NF1). NF1, also referred to as peripheral neurofibromatosis or Von 
Recklinghausen’s disease, is one of the most common human genetic diseases. It has an 
incidence of one in 3000-4000 individuals and equally affects males and females, as it is 
inherited as an autosomal-dominant trait. Spontaneous mutations occur in 50% of cases; 
therefore, the NF1 locus may represent a mutational hotspot in the human genome. All 
affected individuals are heterozygous for loss-of-function mutations in NF1 gene; because 
homozygosity in murine models has been shown to be lethal to embryos (Jacks et al., 
1994), it is believed that one functional NF1 allele is necessary for survival. Some 
individuals demonstrate NF1 features in a localized pattern; this syndrome is termed 
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segmental neurofibromatosis, and this phenotype is likely owing to a postzygotic, somatic 
mutation of the NF1 gene in an early stage of fetal development (somatic mosaicism). 
 
Table 1. Diagnostic criteria for neurofibromatosis type 1 (Gutmann et al., 1997). 
NF1 displays a 100% penetrance, but expressivity is extremely variable. Patients affected 
by this disease show defects in tissues derived from the neural crest, which lead to a wide 
spectrum of phenotypic manifestations, including developmental, pigment and neoplastic 
aberrations (Cichowski and Jacks, 2001). Some diagnostic criteria have been established 
(Gutmann et al., 1997) (Table 1) and they include aberrant pigmentation of the skin (caf  
au lait macules), freckling in non-sun-exposed regions, benign pigmented hamartomas of 
the iris (Lisch nodules), and malformations of the skeletal and cardiovascular systems.  
 
Table 2. Key clinical features of Neurofibromatosis type 1 (Le and Parada, 2007). 
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NF1 patients are also at a higher risk of developing certain tumors, most notably optic 
pathway gliomas and neurofibromas, and exhibit a less penetrant variety of additional 
pathologies of the skin, nervous system, bones, endocrine organs, blood vessels and the 
eyes (Le and Parada, 2007) (Table 2). Furthermore, learning disabilities are one of the 
most common features in children with NF1, seen in 40% to 60% of patients; this is often 
accompanied by attention deficit disorder (Gutmann et al., 1997). 
1.4.6. Neurofibromin structure and function 
Neurofibromin is the protein product of NF1 gene which is located on human 
chromosome 17q11.2 and was identified by positional cloning in 1990 (Ballester et al., 
1990; Xu et al., 1990). It spans over 350kb of genomic DNA and has 60 exons. The NF1 
gene produces an 11- to 13-kb messenger ribonucleic acid (mRNA) that is expressed in 
almost all tissues (Wallace et al., 1990). There are alternatively spliced NF1 mRNA 
isoforms, and, depending on the tissue, they are differentially expressed (Daston et al., 
1992). Neurofibromin is a large peptide (about 250 kDa) composed by 2818 amino acids 
in humans and 2820 amino acids in mice (Gutmann et al., 1991). It is ubiquitously 
expressed during embryonic development and it is also present in a variety of cell types in 
adults (Gutmann et al., 1995), but it is most abundant in the nervous system, where it is 
found in neurons, oligodendrocytes, and Schwann cells (Daston et al., 1992). 
Sequence analysis of neurofibromin reveals a region of homology with the catalytic 
domain of the mammalian p120-Ras-GAP, a GTPase-activating protein (GAP) for the Ras 
family of proto-oncogenes (Xu et al., 1990). Moreover, neurofibromin shows an extended 
similarity with the Saccharomyces cerevisiae Ras-GAP proteins IRA1 and IRA2 (Ballester et 
al., 1990). Exons 20-27a of neurofibromin encode this “GAP related domain” (GRD), which 
induces the conversion of Ras from its active GTP-bound conformation to its inactive 
GDP-bound form (Fig. 21).  
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Figure 21. Loss of neurofibromin deregulates Ras signaling. In response to growth factors, receptor tyrosine kinases (in 
the example EGFR) recruit a guanine nucleotide exchange factor Sos, which activates Ras. In its active, GTP-bound, 
form, Ras initiates several signaling cascades, including the MAPK and PI3K pathways, in order to regulate cell growth, 
survival, and proliferation. Functional loss of neurofibromin compromises Ras inactivation and drives aberrant Ras-
dependent signaling, which contributes to tumor formation and progression (Dilworth et al., 2006). 
Ras is activated at the plasma membrane upon binding of growth factor receptors to 
specific ligands, triggering the recruitment of a complex containing the adapter protein 
growth factor receptor bound protein 2 (Grb2) and the Ras guanine nucleotide exchange 
factor Sos, which catalyzes Ras switch to its GTP-bound state. This active form of Ras then 
binds and activates the kinase Raf and phosphatidylinositol 3-kinase (PI3K), which are the 
apical inducers of two kinase signaling cascades (Fig. 22) (Le and Parada, 2007). 
Neurofibromin, via its GRD, exerts a reverse effect on Ras by increasing its GTP hydrolysis 
rate; as an unrestrained Ras activity is a major oncogenic determinant (see section 
1.2.1.5) neurofibromin acts as a tumor suppressor protein. Many NF1-deficient tumors 
exhibit elevated levels of Ras-GTP, supporting the observation that neurofibromin is a key 
regulator of Ras signaling. Moreover, direct inhibition of Ras (with farnesyltransferase 
inhibitors) or of Ras pathway molecules (with MEK and AKT inhibitors) as well as 
replacement of the NF1-GRD reverses the proliferative phenotype of NF1 deficient cells 
(Hiatt et al., 2001; Kim et al., 1997). These results strongly suggest that the tumorigenic 
potential conferred by loss of neurofibromin at least partially results from the growth 
advantage provided by dysregulated Ras activity.  
Moreover, dysregulation in the Ras signaling pathway has been shown to play a key role 
in another clinical manifestation of NF1 patients: learning and memory disabilities. 
Indeed, Nf1+/- mice present learning deficits (Costa et al., 2002; Li et al., 2005), with 
increased GABA (γ-amino butyric acid)-mediated inhibition and specific deficits in long-
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term potentiation, which can be reversed by decreasing Ras function by genetic and 
pharmacological manipulations. These results indicate that increased Ras activity, as a 
consequence of NF1 mutations, is at least partially responsible for the learning and 
memory disabilities seen in Nf1 mutant mice and, by analogy, suggest a link to the 
intellectual deficits described in patients. 
The connection between NF1 loss and the presence of learning deficits has also been 
related to the ability of neurofibromin to associate with microtubules, which are 
expressed at high level in axonal and dendritic processes of neurons. Interestingly, it has 
been shown that the region of the protein that is critical for this interaction resides within 
the GRD (Xu and Gutmann, 1997). Although microtubules may be important for neuronal 
connection and neurite outgrowth, the exact function of neurofibromin relative to 
microtubules is still under investigation. In regard to this, a recent work has demonstrated 
that neurofibromin interacts with the cytoplasmic Dynein Heavy Chain1 (DHC) and is 
involved in the correct localization of melanosomes along microtubules in melanocytes 
(Arun et al., 2013). This finding indicates a functional role of neurofibromin in 
melanosome localization which sheds insight into a possible molecular mechanism 
underlying Café au lait macules formation in NF1 affected individuals. 
 
Figure 22. Interactions of neurofibromin with different cell signaling pathways. Neurofibromin accelerates inactivation 
of active GTP-bound Ras; therefore, Nf1 loss results in increased Ras activity and dysregulated cell growth. 
Neurofibromin may also be required for cAMP- and PKA-mediated gene transcription. In addition, it also associates with 
microtubules (Trovo-Marqui and Tajara, 2006). 
The Ras-GAP domain of neurofibromin comprises only 10% of the entire polypeptide, 
which has raised the possibility that other regions of the molecule are important for 
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modulating cell growth or other processes related to NF1 disease. Initial studies in 
Drosophila melanogaster have shown that neurofibromin regulates G-protein-stimulated 
adenylate cyclase (AC) activity. The Drosophila NF1 protein is highly conserved, showing 
60% identity of its 2803 amino acids with human NF1. Unlike Nf1-deficient mice, Nf1 null 
mutant flies are viable and fertile; however, they are smaller in body size and this 
phenotype can be rescued, not by attenuating Ras activity but by increasing cAMP 
production through an increased expression of activated protein kinase A (PKA) (The et 
al., 1997). Thus, NF1 and PKA appear to interact in a pathway that controls the overall 
growth of Drosophila. Moreover, at the neuromuscular junction of Drosophila, 
neurofibromin is essential for the activation of the AC/cAMP pathway following 
neuropeptide stimulation which acts on G-protein-coupled receptors (Guo et al., 1997). 
Beside this, the cAMP concentration was significantly lower in extracts of mouse Nf1-/- 
neurons stimulated with GTPγS, a non-hydrolyzable or slowly-hydrolyzable G-protein-
activating analog of guanosine triphosphate, providing the first evidence that 
neurofibromin has additional functions beside Ras regulation also in mammalian cells 
(Tong et al., 2002). Because Drosophila mutants in adenylyl cyclase activity showed 
learning and short-term memory defects, NF1 was hypothesized to affect learning 
through its control of the AC/cAMP pathway. Indeed, it has been shown that NF1-
dependent activation of the adenylyl cyclase pathway is essential for mediating 
Drosophila learning and short-term memory, and that NF1 affects these processes 
independently of its developmental effects observed in mutant flies (Guo et al., 2000). 
These results suggest that some of the NF1 clinical abnormalities, such as short stature 
and learning disabilities, may also result from non-Ras neurofibromin functions in specific 
cell types whereas other features, like tumor formation, involve hyper-activation of Ras. 
Collectively these findings argue that defects in neurofibromin function may affect 
different intracellular signaling pathways which depend on the cell type. 
To date, neurofibromin is known to have an additional functional domain, the Sec14p-like 
domain (Aravind et al., 1999) which is located between amino acids 1545-1816 (Fig. 23) 
and is homologous to the yeast Sec14p, a protein involved in the regulation of 
intracellular proteins and lipid trafficking. This domain belongs to a bipartite structural 
module that includes also a pleckstrin homology (PH)-like domain which is considered 
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responsible for the regulation of the neighboring NF1-Sec domain. Even though the 
biological role of Sec14p domain in NF1 is currently unknown, prediction of a Sec14p-like 
lipid binding domain in neurofibromin opens new lines of investigation of its Ras-GAP 
function in terms of regulation by lipids, and suggests that neurofibromin can be involved 
in other transduction pathways. 
 
Figure 23. Diagram illustrating known functional domains within neurofibromin. Domains are indicated as follows: 
CSRD, cysteine/serine-rich domain; TBD, tubulin-binding domain; GRD, GAP-related domain; Sec14/PH, Sec14-
homologous domain and pleckstrin homology domain; NLS, nuclear localization sequence. Numbers above each 
subdomain indicate the positions of the corresponding amino acids within the 2818 amino acid length of the human 
neurofibromin protein (Brossier and Carroll, 2012). 
1.4.7. Neurofibromin localization 
Even though the Ras-GAP activity currently appears to represent the only clearly defined 
biochemical function of this giant protein, a number of interaction partners of 
neurofibromin have been reported: PKA, protein kinase C (PKC), caveolin-1, focal 
adhesion kinase, tubulin, amyloid precursor protein, syndecan, kinesin-1, nuclear PML-
bodies, the UBX-UBD protein ETEA and p97/VCP. Neurofibromin could interact with 
different partners also depending on its dynamic intracellular movement which regulates 
not only protein localization, but also protein function. Neurofibromin appears to be 
predominantly cytoplasmic, with different cell types displaying a variable subcellular 
localization. Some studies have also observed neurofibromin in the nucleus as it contains 
a nuclear localization sequence (NLS) at the C-terminus (Vandenbroucke et al., 2004). The 
possible function of neurofibromin within the nucleus remains unknown. Translocation to 
the nuclear compartment could be a mechanism to regulate the GAP function of 
neurofibromin by sequestration in the nucleus, as Ras is located at the plasma 
membrane. 
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It is possible that during development, the subcellular targeting of neurofibromin 
depends on posttranslational modifications, such as phosphorylation, to regulate the 
targeting of proteins. Indeed, neurofibromin contains multiple PKA and PKC serine or 
threonine phosphorylation consensus sites which are located within the N-terminus of 
neurofibromin and, in particular, in the cysteine-rich domain (CSRD). EGF stimulation was 
shown to increase the association of neurofibromin with actin through a PKC-dependent 
phosphorylation of neurofibromin. Moreover, this modification increases the Ras-GAP 
activity of neurofibromin (Mangoura et al., 2006). 
1.4.8. Neurofibromin degradation 
Neurofibromin is dynamically regulated by the proteasome, and its degradation and re-
expression are essential for maintaining appropriate levels of Ras-GTP (Cichowski et al., 
2003). Degradation is rapidly triggered in response to a variety of growth factor and 
requires sequences adjacent to the catalytic GAP-related domain of neurofibromin. 
However, whereas degradation is rapid, neurofibromin levels are re-elevated shortly after 
growth factor stimulation. Accordingly, Nf1-deficient mouse fibroblasts exhibit an 
enhanced activation of Ras, prolonged Ras and ERK activities, and proliferate in response 
to sub-threshold levels of growth factors. Thus, the dynamic proteasomal regulation of 
neurofibromin represents an important mechanism of controlling both the amplitude and 
the duration of Ras-mediated signaling. Like p53, neurofibromin can be inactivated in 
cancer by both mutations and excessive proteasomal destruction; however, little is 
known about the mechanisms that underlie this latter process. Only recently it has been 
shown that the E3 ligase Cullin 3 and the BTB adaptor protein KBTBD7 control the 
regulated proteasomal degradation of neurofibromin and are responsible for the 
pathogenic destabilization of neurofibromin in some glioblastoma cell lines (Hollstein and 
Cichowski, 2013). 
1.4.9. NF1 as a tumor predisposition syndrome 
NF1 is a genetic condition that increases the predisposition to tumor development. The 
most common tumor seen in individuals with NF1 is the neurofibroma, followed by optic 
pathway glioma which is seen in 15-20% of children with NF1. Moreover, NF1 patients 
can develop malignancies among which pheochromocytomas, juvenile chronic 
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myelogenous leukemia, malignant astrocytoma, rhadomyosarcoma of the genito-urinary 
tract, duodenal carcinoid, somatostatinoma and parathyroid adenoma (Le and Parada, 
2007). The fact that not all NF1 patients succumb to malignancy implies that other genetic 
and non-genetic factors greatly influence NF1-associated tumor susceptibility. 
Given the role of neurofibromin in regulating Ras activity, NF1 gene is considered a tumor 
suppressor, even if a rigorous testing of this is still lacking. Nf1+/- mice are tumor prone 
and develop two of the malignancies associated with NF1: pheochromocytoma and 
myeloid leukemia (Jacks et al., 1994). In both tumor types, loss of the wild-type allele has 
been observed at high frequency. Moreover, both copies of the NF1 gene are mutated in 
most of NF1 tumors and studies have correlated inactivation of both NF1 alleles with 
deletions of the somatic NF1 gene for benign cutaneous neurofibromas, plexiform 
neurofibromas, malignant peripheral nerve sheath tumors, pheochromocytomas, and 
juvenile myelomonocytic leukemias from NF1 patients (Gottfried et al., 2006).  
 
Table 3. Inactivation of NF1 gene (Gottfried et al., 2006). 
Second hit inactivation of the remaining allele may occur through several different 
mechanisms: chromosome rearrangements, deletion of the entire gene, intragenic 
deletions, insertions and mutations. Furthermore, mutations may occur in noncoding 
regions, and methylation or transcription repression could silence NF1 gene expression 
without a mutation. Point mutations affecting the correct splicing of the NF1 gene are a 
common cause of NF1 (Ars et al., 2000), and they are responsible for both somatic and 
germline mutations. Most mutations in NF1 patients are thought to result in truncation of 
the protein product, which would result in an inactive protein and decreased amounts of 
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active neurofibromin. Small intragenic deletions and insertions account for a third of all 
mutations (Table 3).  
Particular mutations are not typically associated with distinct phenotypic expressions of 
NF1, and several studies have been unable to find any genotype-phenotype correlation. 
The marked clinical variability between multiple affected relatives with the same germline 
mutation may be owing to the nature, timing, and location of the second hit mutation at 
the NF1 locus. Variants of other unknown genes may also modify the expression of the 
disease and result in distinct phenotypes. Moreover, somatic mosaicism is another 
potential cause of inter-individual phenotypic variation. 
1.4.10. Neurofibromas 
The hallmark feature of the disease is the formation of multiple peripheral nerve sheath 
tumors, neurofibromas, which can arise as dermal lesions or grow internally along the 
plexus of major peripheral nerves. While these lesions are benign, they can be debilitating 
and deforming. In addition, a subset of these tumors can progress to malignant 
neurofibrosarcomas. Neurofibromas are rarely present in childhood, but develop during 
puberty and pregnancy, suggesting a hormonal influence on tumor growth. 
- Dermal Neurofibromas 
The most common type of neurofibroma can arise from small nerve radicals or larger 
nerve branches and grow as discrete lesions in the dermis or epidermis ranging from 0.1 
to several centimeters in diameter. They are collectively called dermal neurofibromas and 
patients can develop thousands of them which, depending on location, can be painful and 
disfiguring. One of the key features of neurofibromas is their heterogeneity as they are 
composed of all cell types normally found in the peripheral nerve (Fig. 24). However, the 
structure of the nerve fascicle seems to be highly disorganized, with increased number of 
Schwann cells and fibroblasts, increased collagen deposition, extensive mast cell 
infiltration and disruption of the perineurium. Moreover, unlike in the normal nerve, the 
majority of Schwann cells in neurofibromas are found dissociated from axons and axonal 
degeneration is present. 
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Figure 24. Structure of normal nerves and neurofibromas. Diagram showing a cross-section of (a) a normal nerve 
fascicle and (b) the aberrant structure of nerve fascicles in neurofibromas (Parrinello and Lloyd, 2009). 
- Plexiform neurofibromas 
In contrast to dermal neurofibromas, which are typically small, plexiform neurofibromas 
can develop internally along the plexus of major peripheral nerves and become quite 
large, involving an entire limb or body region. They occur in about 30% of NF1 individuals 
and are considered as congenital lesions. While these are benign tumors, they can be 
debilitating and can progress to malignancy. Indeed, plexiform neurofibromas harbor a 
5% lifetime risk of transformation into malignant peripheral nerve sheath tumors 
(MPNSTs). These are highly malignant and metastatic cancers with a high mortality and a 
poor response to chemotherapy and radiation. The difference in the mechanism of 
tumorigenesis between cutaneous neurofibromas and plexiform is unclear; however, the 
timing of their development as well as their growth properties may indicate differences in 
the mechanism of tumor initiation. 
1.4.10.1. Origin of neurofibromas 
The molecular mechanisms underlying tumor development in NF1 have been obscure. 
Although second hit mutations affecting the inherited wild-type NF1 allele have been 
clearly identified in the myeloid leukemias and pheochromocytomas in NF1 patients, such 
mutations have been reported for only a small number of neurofibromas. The difficulty in 
detecting mutations may be due in part to the complex nature of these lesions, which are 
composed of multiple cell types, not all of which are expected to develop a second 
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mutation. Moreover, it has also been suggested that NF1 heterozygosity may be sufficient 
for development of benign neurofibromas (haplo-insufficiency), with full loss of NF1 
function being restricted to the progression to MPNSTs. 
Research over the past decade using mouse models has greatly enhanced our knowledge 
of neurofibroma development and malignant progression in NF1. The mouse and human 
NF1 genes are highly related, the amino acid sequence of neurofibromin is 98% identical, 
and there is also significant similarity between the non-coding regions of the mRNA. Mice 
homozygous for null Nf1 mutation in exon 31, a region that is often mutated in human 
NF1 patients, are embryonic lethal at E13.5 secondary to defective heart and 
malformation of the major cardiac outflow tracts. Defects in renal, hepatic and skeletal 
muscle development were also observed; however, nervous system pathology was 
limited to enlargement of sympathetic ganglia secondary to neuronal hyperplasia 
(Brannan et al., 1994; Gottfried et al., 2006; Jacks et al., 1994). Heterozygous Nf1 mutant 
mice are viable and only have increased incidence of pheochromocytomas and myeloid 
leukemias beyond 10- to 12-month old; however, they do not develop peripheral nerve 
sheath tumors or other characteristic symptoms of human NF1. One possible explanation 
for this observation is that LOH necessary for neurofibroma development is impaired in 
mice. Perhaps, given the shorter time of gestation and lifespan compared with humans, 
the Nf1+/- mice do not have the necessary window of opportunity to undergo effective 
LOH in target cells to initiate neurofibroma formation. Cichowski et al. (1999) addressed 
this issue elegantly when they created chimeric mice by injecting Nf1-/- ES cells into wild-
type blastocysts. These mice developed microscopic plexiform neurofibromas derived 
from the injected ES cells, demonstrating the requirement of Nf1 homozygosity for tumor 
formation. However, the degree of chimerism in these mice occurs randomly and cannot 
be controlled genetically. As a result, it was difficult to establish the target cell or whether 
other cell types contribute to the tumorigenesis.  
As in human neurofibromas Schwann cells were the most common cell type present in 
neurofibromas it was hypothesized that this cell type, or their precursors, could be the 
initiating cell for tumor development. Schwann cell-specific Nf1-deficient mice were 
derived by crossing Nf1flox/flox mice with the Krox20-cre transgenic mice, an embryonic 
Schwann cell-specific promoter (Zhu et al., 2002). Mice with a conditional knockout of Nf1 
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only in embryonic Schwann cells, but wild-type in all other cell lineages (Nf1flox/flox; 
Krox20-Cre), exhibit microscopic hyperplasia in sensory ganglia but do not develop 
neurofibromas. However, when mice homozygous for Nf1 mutation (Nf1-/-) in Schwann 
cells but heterozygous for Nf1 (Nf1+/-) in all other somatic cells (Nf1flox/-; Krox20-Cre) were 
generated, these mice developed multiple classic plexiform neurofibromas with a massive 
degranulating mast cell infiltration, modeling human neurofibroma (Table 4). These 
genetic studies implied the Schwann cell origin for neurofibroma. Nevertheless, in 
addition to nullizygosity at Nf1 locus in Schwann cells, haploinsufficiency of Nf1 in the 
tumor microenvironment is also required for the tumorigenesis. 
 
Table 4. Genetically engineered mouse models of neurofibroma formation (part 1). Both nullizygosity at Nf1 locus in 
Schwann cells and haploinsufficiency of NF1 in the somatic tissue are required for neurofibroma (Brossier and Carroll, 
2012). 
1.4.10.2. Timing in Nf1 loss 
Even though it is well established that neurofibromas arise from Schwann cells that 
undergo loss of heterozygosity (LOH) at the NF1 locus, the specific cell type within the 
Schwann cell lineage in which this occurs has been the topic of much debate. The 
Schwann cell lineage is well characterized and specific markers for the different cell types 
within the lineage have been identified. Schwann cells originate from migrating neural 
crest stem cells (NCSCs) and develop through two sequential, intermediate glia-
committed stem/progenitor cell types, called Schwann cell precursors and immature 
Schwann cells (Fig. 25) (Mirsky et al., 2008). Around birth, immature Schwann cells 
differentiate into the two main mature Schwann cell types of the peripheral nerve, 
myelinating and non-myelinating Schwann cells. The former myelinate single large-caliber 
axons and the latter wrap multiple small-caliber axons in structures known as Remak 
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bundles. Importantly, Schwann cell progenitors differentiate by late gestation and do not 
persist in the adult peripheral nervous system. Instead, upon nerve injury, the 
requirement for new cells is met by the regenerative ability of mature differentiated 
Schwann cells to transiently de-differentiate to a progenitor-like state (Parrinello and 
Lloyd, 2009). 
  
Figure 25. Schwann cell development. Neural crest cells give rise to a series of cell types in the Schwann cell lineage, 
one or more of which can become a neurofibroma initiating cell (NIC) following biallelic NF1 loss. Plexiform NICs are 
thought to be derived from Schwann cell precursors or their more differentiated progeny in deep peripheral nerves; 
alternative origins such as boundary cap cell or satellite cells have also been proposed. Another progenitor population 
arising from the neural crest has been located in the dermis, and dermal NICs may arise instead from these skin-derived 
precursors (SKPs) or their progeny. Times indicated are the embryonic days (E) at which specific Schwann cell 
precursors appear in the mouse. Listed below each cell type are useful markers of specific developmental stages and 
promoters which are active at these stages (Brossier and Carroll, 2012). 
Three independent groups have recently tested whether neurofibromas originate from 
embryonic stem cells or differentiated adult cells by generating conditional mouse models 
in which Nf1 LOH was induced in the Schwann cell lineage at different times during 
embryonic development (Table 5) (Joseph et al., 2008; Wu et al., 2008; Zheng et al., 
2008). Elimination of Nf1 expression in neural crest cells, the earliest stage in Schwannian 
differentiation, was achieved by mating Nf1flox/− mice with Wnt1-Cre, Mpz-Cre, and Pax3-
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Cre animals. Although these mice had abnormal sympathetic ganglia and adrenal glands 
and died at birth, they did not develop neurofibromas. Given the early death of these 
animals, the observation of the tumorigenic effects of Nf1 loss is prevented. However, the 
authors observed that Nf1 loss significantly increased the frequency of stem cells at early 
embryonic stages but they were no more detectable by late gestation (Joseph et al., 
2008) indicating that early progenitors with stem cell properties do not persist in the 
adult where they could give rise to neurofibroma. This observation together with the fact 
that Nf1flox/−; Krox20-Cre mice do develop neurofibromas, and Krox20 is not expressed in 
neural crest cells, argues that Nf1 loss in neural crest cells is not required for 
neurofibroma pathogenesis. 
 
Table 5. Genetically engineered mouse models of neurofibroma formation (part 2). The timing of neurofibromin 
inactivation is the key determinant of neurofibroma formation in the peripheral nerve, with Nf1 loss restricted to a 
narrow window of embryonic development corresponding to the late precursor-early immature Schwann cell stage 
(E12-13) (Brossier and Carroll, 2012). 
Mouse models in which Nf1 was ablated in Schwann cell precursors (SCPs; also known as 
neural crest stem cells) were obtained using 3.9Periostin-Cre (which is active in SCPs by 
E11) and P0a-Cre (expressed in SCPs beginning at E12.5) driver lines. While the majority 
of Nf1flox/−; 3.9Periosin-Cre animals died by the 4th postnatal week (Joseph et al., 2008), 
Nf1flox/−; P0a-Cre animals survived and formed neurofibromas in adult limb nerve (Zheng 
et al., 2008). Interestingly, the proliferating cells in these neurofibromas were p75+, 
GFAP+ and BLBP−, suggesting that mature non-myelinating Schwann cells rather than 
SCPs were the cell type giving rise to neurofibromas in this model. In keeping with this 
idea, hyper-proliferative non-myelinating Schwann cells were found in the postnatal 
sciatic nerves of Nf1flox/−; P0a-Cre mice prior to neurofibroma development. The time-
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window of tumor development is consistent with findings from Wu and colleagues, who 
showed that recombination of Nf1 driven by the Desert Hedgehog (Dhh) promoter at 
E12.5 in Schwann cell precursors resulted in neurofibroma development in peripheral 
nerve roots, but not in nerve trunks (Wu et al., 2008). Unlike the tumors arising in 
Nf1flox/−; P0a-Cre mice, neurofibromas developing in Nf1flox/flox; Dhh-Cre mice contained 
numerous BLBP+ cells, suggesting that immature Schwann cells were the progenitors for 
these tumors. Interestingly, the development of neurofibromas in Nf1flox/flox; Dhh-Cre mice 
occurred despite the presence of a wild-type Nf1 microenvironment; no evidence was 
found for Cre-mediated recombination in mast cells, endothelial cells or endoneurial 
fibroblasts, despite the fact that Dhh-expressing progenitors capable of differentiating 
into both Schwann cells and endoneurial fibroblasts have been found in peripheral nerve 
(Joseph et al., 2004) (Fig. 26). Therefore, neoplastic transformation of NCSCs or non-
neuronal restricted nerve progenitors could potentially yield clonal tumors containing 
both Schwann cells and fibroblasts. 
 
Figure 26. Model of peripheral nerve development. NCSCs self-renew in peripheral nerves to generate additional 
NCSCs, as well as undergoing restriction under the influence of Nrg1, Delta and Bmp4. The resulting restricted 
progenitors lack neuronal potential (non-neuronal) but undergo lineage commitment to form both glial and 
myofibroblast progenitors. Glial progenitors differentiate to form both myelinating and non-myelinating Schwann cells, 
and myofibroblast progenitors differentiate to form endoneurial fibroblasts (Joseph et al., 2004). 
Given these contradictory results, it is not yet clear whether the neoplastic Schwann cells 
within plexiform neurofibromas are derived from mature non-myelinating Schwann cells, 
immature Schwann cells or both cell types. The possibility that these neoplastic Schwann 
cells arise from another source such as boundary cap cells also has not yet been ruled 
out. Intriguingly, these findings could have implications for our understanding of the 
59 
 
enormous variability in the severity of the human disease, even among members of the 
same family. 
Given the marked differences in the clinical behavior of dermal and plexiform 
neurofibromas, it is possible that the neoplastic cells in these neurofibroma subtypes are 
derived from distinct progenitors. Neural-crest derived precursor cells capable of both 
Schwannian and melanocytic differentiation, termed skin-derived precursors (SKPs) (Fig. 
25), are present in the dermis of adult mice. Consistent with the hypothesis that SKPs give 
rise to dermal neurofibromas, topical administration of tamoxifen to neonatal Nf1flox/−; 
CMV-CreERT2; Rosa26-LacZ(stop) mice results in dermal neurofibroma formation at the 
site of tamoxifen administration (Le et al., 2009). Further, SKPs isolated from these 
animals and treated ex vivo with tamoxifen to inactivate Nf1 were also capable of 
generating neurofibromas upon autologous subcutaneous transplantation into pregnant 
mice, indicating that these progenitors (and not other cell types residing in the dermis) 
were the cell of origin of the dermal neurofibromas. Interestingly, Nf1−/− SKPs were also 
capable of forming plexiform neurofibromas when auto-grafted into sciatic nerves. Thus, 
while SKPs residing in the dermis may be the cell of origin of dermal neurofibromas, these 
cells are apparently highly similar to the neurofibroma-initiating cells in peripheral nerve. 
The distinct clinical behavior of these tumors may primarily reflect differences in their 
microenvironment rather than their cell of origin (Brossier and Carroll, 2012). 
1.4.10.3. Role of tumor microenvironment 
Zhu and colleagues showed that Nf1 loss in Schwann cell progenitors alone is not 
sufficient for tumor environment, as a heterozygous environment is needed (Zhu et al., 
2002). In neurofibromas, Nf1+/− fibroblasts demonstrate abnormal responses to cytokines, 
increased collagen deposition, and increased proliferation. Nf1+/− mast cells have 
increased infiltration to pre-neoplastic peripheral nerves in comparison with wild-type 
mast cells and have increased proliferation in vitro and in vivo (Gottfried et al., 2006). 
These cells appear to function as critical intermediaries between Nf1−/− Schwann cells and 
other Nf1+/− cell types in the microenvironment. Nf1−/− Schwann cells secrete elevated 
levels of Kit ligand, a growth factor which activates the c-Kit membrane tyrosine kinase 
(Fig. 27). Nf1+/− mast cells show increased c-Kit expression and an enhanced chemotactic 
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response to Kit ligand relative to wild-type mast cells, leading to increased recruitment of 
these cells into the nascent tumor (Viskochil, 2003). Kit ligand also induces enhanced 
activation, degranulation, and TGF-β secretion in Nf1+/− mast cells. TGF-β in turn acts 
upon Nf1+/− fibroblasts and promotes increased production of collagen, a molecule which 
is found in abundance in neurofibromas. 
 
Figure 27. Molecular pathways involved in mast cell recruitment to neurofibromas. A neurofibromin-deficient 
Schwann cell (Nf1
–/–
) secretes five times the normal Kit ligand, which serves as a chemo-attractant for mast cells 
expressing c-Kit. Mast cell migration is mediated by the Ras/PI3K/Rac2 signal transduction pathway, which is enhanced 
in Nf1
+/–
 cells. Although not shown, endothelial cells also play a role in mast cell migration through the interaction of 
the endothelial cell VCAM-1 receptor and α4β1 integrin of the mast cell (Viskochil, 2003). 
An essential role for mast cells in neurofibroma formation has been elegantly 
demonstrated using bone marrow transplantation in knock-out mice (Table 6). As noted 
above, Nf1flox/flox; Krox20-Cre mice do not develop neurofibromas. However, when 
Nf1flox/flox; Krox20-Cre mice were lethally irradiated and transplanted with Nf1+/− bone 
marrow, they developed multiple plexiform neurofibromas that were infiltrated by donor 
mast cells (Yang et al., 2008). In contrast, when donor marrow from Nf1+/− mice with 
hypoactive c-Kit receptors (Nf1+/−; c-KitW41/W41 mice) was used, no tumors formed, 
indicating that c-Kit signaling in bone marrow-derived elements was critical for 
neurofibroma formation. Consistent with the hypothesis that Nf1+/− mast cells are 
critically important for neurofibroma pathogenesis, no neurofibromas formed in lethally 
irradiated Nf1flox/−; Krox20-cre mice transplanted with wild-type bone marrow, despite the 
presence of Nf1 haploinsufficient fibroblasts and endothelial cells in the peripheral nerve. 
61 
 
 
Table 6. Genetically engineered mouse models of neurofibroma formation (part 3). The timing of neurofibromin 
inactivation is the key determinant of neurofibroma formation in the peripheral nerve, with Nf1 loss restricted to a 
narrow window of embryonic development corresponding to the late precursor-early immature Schwann cell stage 
(E12-13) (Brossier and Carroll, 2012). 
Although it is clear that mast cell recruitment is essential for neurofibroma formation and 
that Nf1 haploinsufficiency in other cell types cannot overcome this requirement, it 
remains to be determined whether Nf1 haploinsufficiency in these other cell types 
promotes neurofibroma growth. It is also unclear what pro-tumorigenic function(s) are 
performed by the recruited mast cells after their arrival in the nascent neurofibroma and 
whether these effects are directed at the neoplastic Schwann cells or other intra-tumoral 
cell types (Brossier and Carroll, 2012). At present, an entire series of pro-tumorigenic 
interactions between the various cell types composing a neurofibroma can be envisioned 
(Fig. 28). However, the existence and functional significance of most of these interactions 
remains to be determined. 
 
Figure 28. Established and potential interactions between Nf1
−/−
 Schwann cells and other Nf1 haploinsufficient cell 
types intrinsic to peripheral nerve. Established interactions are depicted with solid black arrows and font, while 
potential interactions are depicted with gray dashed arrows labeled with question marks (Brossier and Carroll, 2012). 
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1.5. Aim of the project 
Our interest is toward the investigation of how oncogenic signaling cascades affect 
mitochondrial physiology. Indeed, we believe that mitochondria play a pivotal role in 
shaping the oncogenic signaling cascade and readjustments in mitochondrial physiology 
can contribute to the tumorigenic process. 
In particular, we are focused on the Ras-MEK-ERK signaling pathways which display a 
mitochondrial branch, as a fraction of ERK is present in the mitochondrial matrix of cancer 
cells. We would like to investigate which is the impact of the hyper-activation of this 
signaling cascade on mitochondrial physiology, in terms of respiration and mechanisms of 
cell death resistance, in extreme models of cancer cells (ρ0 cells) and when this pathway is 
deregulated by modifications of upstream regulators (neurofibromin loss). We would like 
to understand to which extent mitochondrial rewiring contributes to the neoplastic 
process and how these changes are achieved through the deregulation of oncogenic 
signaling cascades. 
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2. Materials and Methods 
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2.1.  Chemicals and antibodies 
Tetramethylrhodamine methyl ester (TMRM) and ATP determination Kit were from 
Molecular Probes (Eugene, OR); FITC-conjugated annexin-V was from Boehringer 
Mannheim (Indianapolis, IN); indirubin-3′-oxime and CsA were from Calbiochem (San 
Diego, CA); cyclosporin H (CsH) was a generous gift of Dr. Urs Ruegg, Geneva; all other 
chemicals were from Sigma (Milan, Italy).  
Mouse monoclonal anti GSK-3α/β, Grim19, SDHA and UQCRC1, goat polyclonal anti 
calnexin, HK II and VDAC1, and rabbit polyclonal anti ERK2, PARP and TOM20 antibodies 
were from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit polyclonal anti phospho-
ERK1/2 (Thr202/Tyr204) and anti phospho GSK-3α/β (Ser21/9) and rabbit monoclonal anti 
caspase-3 antibodies were from Cell Signaling (Beverly, MA); mouse monoclonal anti 
phospho-Ser/Thr, GAPDH, CyP-D and anti prohibitin antibodies were from Qiagen, 
Millipore, Calbiochem and Lab Vision (Fremont, CA), respectively; mouse monoclonal anti 
HSP90 and TRAP1 antibodies were from BD Biosciences; rabbit polyclonal anti AIF and 
NF1 antibodies were from Exalpha Biologicals (Shirley, MA) and Novus Biologicals, 
respectively; the mouse monoclonal OXPHOS antibody cocktail recognizing CI (NDUFB8), 
CII (SDHB), CIII (core2), CIV (COXII) and CV (α), and the mouse monoclonal anti NDUFS3 
antibody were from Mito-Sciences (Eugene, OR); rabbit monoclonal anti NDUFS1 was 
from Abcam. Peptides MIASHLLAYFFTELNβA-GYGRKKRRQRRRG (TAT-HK II) and 
GYGRKKRRQRRRG-βA-EEEAKNAAAKLAVEILNKEKK (TAT-Ctrl) were synthesized by a solid 
phase method using an automatized peptide synthesizer (model 431-A, Applied 
Biosystems, Foster City, CA). 
2.2.  Cell cultures and transfections 
The human 143B osteosarcoma and the derived 206 ρ0 cell lines were kindly provided by 
Lodovica Vergani (Deparment of Neurosciences, University of Padova, Padova, Italy). 
Mouse embryonic fibroblasts (MEFs) cells from C57BL/6J mice of three different 
genotypes (Nf1+/+, Nf1+/- and Nf1-/-), immortalized by transfection with SV40 whole 
genome DNA, were obtained from Dr R. Stein (Tel Aviv University, Ramat Aviv, Israel). 
143B and MEFs cells were grown in high glucose (4500 mg/L) Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml 
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penicillin, and 100 µg/ml streptomycin (Invitrogen) in a humidified atmosphere of 5% 
CO2/95% air at 37°C. Medium of ρ
0 cells was supplemented with 50 mg/L uridine, 
essential amino acids and vitamins. 
TRAP1 stable interference of human cells was achieved by transfecting cells with a panel 
of TRAP1 shRNAs from Sigma; scrambled shRNAs were always used as negative controls. 
Cells were transfected with Lipofectamine 2000 (Invitrogen) and stable interfered cells 
were selected in 2 µg/ml puromycin (Sigma). 
2.3.  Epifluorescence microscopy 
Mitochondrial membrane potential (Δψm) was measured either by epifluorescence 
microscopy or by flow cytometry (see below). For epifluorescence microscopy cells were 
seeded onto 24 mm-diameter round glass coverslips and grown for 2 days in DMEM. 
Δψm was measured based on the accumulation of TMRM in the presence of CsH, which 
inhibits the multidrug resistance pump but not the PTP. Cells were incubated in 
bicarbonate- and phenol red-free DMEM supplemented with 10 mM Hepes and 1.6 µM 
CsH and loaded with 20 nM TMRM for 30 min at 37°C. At the end of each experiment, 
mitochondria were fully depolarized by the addition of 4 µM of the protonophore FCCP. 
Cellular fluorescence images were acquired with an Olympus IX71/IX51 inverted 
microscope equipped with a xenon light source for epifluorescence illumination and with 
a 12-bit digital cooled CCD camera (Micromax, Princeton Instruments, Trenton, NJ). For 
detection of fluorescence 568 ± 25 nm bandpass excitation and 585 nm longpass emission 
filter settings were used. Images were collected every 3 min with an exposure time of 100 
msec (6% illumination intensity) using a 40X, 1.3 NA oil immersion objective (Olympus). 
Data were acquired and analyzed using Cell R software (Olympus). Clusters of several 
mitochondria (10–30) were identified as regions of interest, and fields not containing cells 
were taken as the background. Sequential digital images were acquired every minute, and 
the average fluorescence intensity of all relevant regions was recorded and stored for 
subsequent analysis. 
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2.4. Cytofluorimetric analyses 
Flow cytometry recordings were performed to determine cell death, mitochondrial 
membrane potential and mitochondrial mass. Briefly, for cell death analysis cells were 
incubated at 37°C in 135 mM NaCl, 10 mM HEPES, 5 mM CaCl2 (FACS mix solution) with 
FITC-conjugated Annexin-V (Boehringer Mannheim) and propidium iodide (PI, 1 µg/ml; 
Sigma), to detect phosphatidyl-serine exposure on the cell surface (increased FITC-
conjugated Annexin-V staining) and loss of plasma membrane integrity (PI permeability 
and staining); Annexin-V and PI negative cells were considered viable. For mitochondrial 
membrane potential analysis cells were incubated for 15 min at 37°C in FACS mix solution 
with TMRM (20 nM) and CsH (1.6 µM). For mitochondrial mass analysis cells were 
incubated for 15 min at 37°C in FACS mix solution with 10-N-nonyl acrydine orange (NAO, 
20 nM; Invitrogen), which binds to cardiolipin in mitochondrial membranes. Changes in 
forward and side light scatter were assessed at the same time to measure alterations in 
cell dimension and granularity, respectively. Samples were analyzed on a FACSCanto II 
flow cytometer (Becton Dickinson). Data acquisition and analysis were performed using 
FACSDiva software. 
2.5.  In vitro tumorigenesis assays 
For the soft agar assay, cells were grown in 6 cm Petri dishes covered by a bottom layer 
composed of DMEM medium mixed with low melting point agarose (Promega) at a final 
concentration of 1.0%, and by a top layer of DMEM medium supplemented with 2% 
serum and mixed with low melting point agarose at a final concentration of 0.6%. Cells 
(2.5x105) were added during the preparation of the upper layer, where they remained 
embedded. Dishes were then maintained in a humidified atmosphere of 5% CO2-95% air 
at 37°C for three weeks, changing the medium (DMEM 2% serum) on the top of the two 
layers every 3th day. At the 25th day, dishes were washed in PBS and colonies were stained 
with Crystal Violet 0.005% and analyzed with Image Analyzer custom software. 
2.6.  In vivo tumorigenesis assays 
Experiments were performed in 8-week-old SCID mice (Charles River, Wilmington, MA) 
treated in accordance with the European Community guidelines. Six mice were injected 
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subcutaneously bilaterally in the flanks with 2.5 and 5x106 MEFs in 200 µl of serum-free 
sterile PBS mixed with Matrigel. Tumor growth was evaluated on alternate days by 
calliper measuring. After one month, mice were sacrificed and tumors stored at -80°C. 
2.7.  Cell lysis and mitochondria fractionation 
Total cell extracts were prepared at 4°C in a buffer composed of 150 mM NaCl, 20 mM 
Tris-HCl pH 7.4, 5 mM EDTA, 10% glycerol, 1% Triton X-100 (Lysis Buffer), in the presence 
of phosphatase and protease inhibitors (Sigma). Lysates were then cleared with a 
centrifugation at 18,000 x g for 30 min at 4°C, and proteins were quantified using a BCA 
Protein Assay Kit (Thermo Scientific-Pierce).  
Mitochondria were isolated after cell disruption with a glass-Teflon or electrical potter 
(Sigma) in a buffer composed of 250 mM sucrose, 10 mM Tris-HCl, 0.1 mM EGTA-Tris, pH 
7.4. Nuclei and plasma membrane fractions were separated by a first mild centrifugation 
(700 x g, 10 min); mitochondria were then spinned down at 7,000 x g, 10 min, and washed 
twice (7,000 x g, 10 min each). All procedures were carried out at 4°C. In order to define 
sub-mitochondrial protein localization, isolated mitochondria were digested with trypsin 
at different concentrations at 4°C for 1 hour. Trypsin was then inactivated with a protease 
inhibitor cocktail (Sigma), and mitochondria were lysed and spun at 18,000 x g at 4°C for 
10 min. 
2.8.  Immunoprecipitation and western blotting 
Protein immunoprecipitations were carried out on 4 mg of total cellular extracts. Lysates 
were pre-cleared by incubating them with protein A-Sepharose beads (Sigma) for 1 hour 
at 4°C; they were then incubated in agitation for 18 hours at 4°C with the antibody 
conjugated to fresh protein A-Sepharose beads. Where indicated, an unrelated antibody 
was added as a negative isotype control. Beads were then washed several times in Lysis 
buffer. 
Proteins extracted from total or mitochondrial cell lysates or from immunoprecipitations 
were then boiled for 5 min in Laemmli sample buffer, separated in reducing conditions on 
SDS-polyacrylamide gels and transferred onto Hybond-C Extra membranes (Amersham) 
following standard methods. Primary antibodies were incubated for 16 hours at 4°C, and 
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horseradish peroxidase-conjugated secondary antibodies were added for 1 hour at room 
temperature. Proteins were visualized by enhanced chemiluminescence (Millipore). 
2.9.  Blue native polyacrylamide gel electrophoresis (BN-PAGE) 
BN-PAGE experiments were performed on pellets of mitochondria isolated as described. 
ETC complexes were extracted from 200 µg of mitochondria by resuspending them at 10 
mg/ml in a buffer composed of 1M aminocaproic acid, 50 mM Bis Tris pH 7, in the 
presence of 2% n-dodecyl-β-D-maltoside (DDM) at 4°C. Immediately after extraction 
mitochondria were spinned at 100,000 x g for 30 min and supernatants were loaded on 
1D-Native-PAGE 3-12% Bis-Tris pre-cast gradient gels (Invitrogen) after addition of 
Coomassie Blue G250 (Invitrogen). Bands were visualized after 18 hours of Coomassie 
Blue G-250 staining. Bands corresponding to different ETC complexes were cut and 
subjected to 2D-SDS-PAGE, in order to separate single protein components which were 
identified by Western immunoblotting. 
2.10. ETC complex I and II activity assays 
To measure the enzymatic activity of respiratory chain complexes, cells were 
homogenized with an electric potter (Sigma) in a buffer composed of 250 mM sucrose, 10 
mM Tris-HCl, 0.1 mM EGTA-Tris, pH 7.4, Percoll 10%, protease and phosphatase inhibitors 
and mitochondria were isolated as described above. Mitochondrial enriched fractions 
(20-40 µg per trace) were used for spectrophotometric recordings. 
For complex I activity, the rotenone-sensitive NADH-CoQ oxidoreductase activity was 
detected following the decrease in absorbance due to the oxidation of NADH at 340 nm 
(ε=6.2 mM-1 cm-1). Reaction was performed at 30°C in 10 mM Tris-HCl pH 8 buffer 
containing 5 µM alamethicin, 3 mg/ml BSA, 5 µM sodium azide, 2 µM antimycin A, 65 µM 
Coenzyme Q1, and 100 µM NADH. The NADH-ubiquinone oxidoreductase activity was 
measured for 3-5 min before the addition of rotenone (10 µM), after which the activity 
was measured for an additional 3-5 min. 
Complex II activity was measured by following the reduction of 2-6 
dichlorophenolindophenol (DCPIP) at 600 nM (ε=19.1 mM-1 cm-1). Mitochondria were 
pre-incubated for 10 min at 30°C in a buffer composed of 25 mM potassium phosphate 
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pH 7.2, 20 mM sodium succinate, and 5 µM alamethicin. After the pre-incubation time, 
sodium azide (5 µM), antimycin A (2 µM), rotenone (2 µM) and DCPIP (50 µM) were 
added for 1 min to the medium. Reaction was performed at 30°C and started after the 
addition of an intermediate electron acceptor (Coenzyme Q1, 65 µM). 
Each measurement of ETC complex activity was normalized for citrate synthase (CS) 
activity. To measure CS activity, citrate formation was determined with a 
spectrophotometer as an increase in absorbance at 420 nm at 37°C. Reaction buffer was 
composed of 100 mM Tris-HCl pH 8, 0.1% Triton X-100, 100 µM 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB), 300 µM Acetyl -CoA, and 500 µM Oxaloacetate.  
2.11. Oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) measurements 
The rate of oxygen consumption was assessed in real-time with the XF24 Extracellular 
Flux Analyzer (Seahorse Biosciences), which allows to measure OCR changes after up to 
four sequential additions of compounds. Cells (2x104/well) were plated the day before 
the experiment in a DMEM/10% serum medium; experiments were carried out on 
confluent monolayers. Before starting measurements, cells were placed in a running 
DMEM medium (supplemented with 25 mM glucose, 2 mM glutamine, 1 mM sodium 
pyruvate, and without serum and sodium bicarbonate) and pre-incubated for 1h at 37°C 
in atmospheric CO2. An accurate titration with the uncoupler FCCP was performed for 
each cell type, in order to utilize the FCCP concentration that maximally increases OCR. 
Together with OCR measurements, values of ECAR were also recorded as the absence of 
sodium bicarbonate allows changes in the pH of the medium.  
2.12.  Measurement of mitochondrial Ca2+ retention capacity 
The Ca2+ retention capacity (CRC) assay was used to assess PTP opening in whole cells 
following trains of Ca2+ pulses and measured fluorimetrically at 25°C in the presence of 
the Ca2+ indicator Calcium Green-5N (1 µM; Molecular Probes). Cells were washed in an 
isotonic buffer (130 mM KCl, 1 mM Pi-Tris, 10 mM Tris-Mops, and 0.1 mM EGTA-Tris, pH 
7.4), and then permeabilized with 150 μM digitonin (20 min, 4°C), increasing EGTA to 1 
mM. Digitonin was then eliminated and permeabilized cells were placed in low (10 μM) 
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EGTA in the presence of 2 μM rotenone/5 mM succinate, 10 μM cytochrome c, and 
Calcium Green-5N, which does not permeate mitochondria. Cells were then exposed to 
Ca2+ spikes (5 μM), and fluorescence drops were used to assess mitochondrial Ca2+ 
uptake. PTP opening was detected as a fluorescence increase. Calcium Green-5N 
fluorescence was measured with a Fluoroskan Ascent FL fluorimeter (Thermo Electron 
Corporation). 
2.13. Intracellular ATP determination 
Intracellular ATP was quantified by the luciferin/luciferase method using the ATP 
determination kit by Invitrogen/Molecular Probes following manufacturer’s instructions. 
Cells were kept for two hours in the different experimental conditions, washed with PBS, 
lysed in boiling water to avoid ATPase activity. 2.5 µg of proteins were analyzed in a 100 
µl final volume 96-well plates that were read using a Fluoroskan Ascent FL microplate 
reader. A standard curve was generated using solutions of known ATP concentrations. 
ATP levels were calculated as nmoles ATP/mg of protein and normalized to levels of 
control cultures. 
2.14. Statistics 
Unless otherwise stated each experiment was repeated at least three times. Data 
are presented as average ± S.E. or, for clarity, as representative experiments (see figure 
legends for details). 
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3. RESULTS 
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3.1. Permeability transition pore of ρ0 cells: regulatory mechanisms 
shared with cancer models 
Cells entirely depleted of their mtDNA (ρ0 cells) have no respiration, as mtDNA encodes 
13 essential subunits of respiratory chain complexes and of ATP synthase. Therefore, 
these cells rely entirely on glycolysis for ATP synthesis, and can be maintained in culture 
as long as their medium contains, beside glucose, a pyrimidine and pyruvate. Hydrolysis 
of glycolytic ATP by ATP synthase acting in reverse mode is fundamental for the 
maintenance of the mitochondrial membrane potential of these cells (Buchet and 
Godinot, 1998). Investigators have used ρ0 cells to address the question of whether 
mitochondrial respiratory function is required for apoptosis (Chomyn and Attardi, 2003). 
It has indeed been demonstrated that ρ0 cells are able to undergo apoptosis and release 
cytochrome c from their mitochondria, and are protected from apoptosis by Bcl-2 
overexpression (Jacobson et al., 1993). Concomitantly with cytochrome c release, ρ0 cells 
undergo caspase-3 activation and mitochondrial membrane depolarization, indicating 
that the key apoptotic steps are conserved in cells without functional mitochondrial 
respiration (Jiang et al., 1999). However, occurrence of PTP in ρ0 cells is still debated 
(Kwong et al., 2007) and a formal definition of the role played by OXPHOS complexes in 
PTP regulation is still lacking. 
ρ0 cells have also been used as an extreme model for the study of disorders caused by 
mtDNA mutations (mitochondrial diseases), and as a potential model for the investigation 
of bioenergetics of neoplasias; indeed, ρ0 cells can be considered as possessing an 
extreme ‘Warburg phenotype’ since they completely lack respiration and their ATP 
production is fully uncoupled from oxygen availability. Furthermore, as we have discussed 
in the introduction, several mtDNA mutations and reduction in their copy number have 
been reported in diverse type of tumors (Brandon et al., 2006). Therefore, as a proof of 
principle, we investigated whether ρ0 cells actually possess a PTP and, if so, whether they 
share common PTP regulatory mechanism with cancer cell models: deployment of HK II 
on the mitochondrial surface and presence of a mitochondrial ERK-GSK3 signaling axis 
that regulates the phosphorylation of CyP-D.  
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3.1.1. Paper 
The results of this study are illustrated in the following publication (see Appendix section) 
whose reference is: 
Masgras, I., Rasola, A., and Bernardi, P. (2012). Induction of the permeability transition 
pore in cells depleted of mitochondrial DNA. Biochim. Biophys. Acta 1817, 1860-1866. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
3.2. On the role of neurofibromin in regulation of mitochondrial 
bioenergetics 
We have then investigated the involvement of mitochondrial signaling pathways in cells 
with different neurofibromin expression levels. Our hypothesis was that neurofibromin-
dependent deregulation of the mitochondrial branch of ERK signaling could impact on cell 
metabolism and survival, and therefore on the process of neoplastic transformation. 
3.2.1. Mouse embryonic fibroblasts express neurofibromin, whose depletion 
induces ERK activation 
Nf1+/+, Nf1+/- and Nf1-/- mouse embryonic fibroblasts (MEFs) were analyzed for the 
expression level of neurofibromin, which was in accordance with the different genotypes 
(Fig. 3.1A).  
 
Figure 3.1. ERK is hyper-active upon neurofibromin depletion. (A) Neurofibromin level in MEFs wild-type, 
heterozygous and homozygous for Nf1 deletion. (B) Simplified version of the Ras pathway (Cichowski and Jacks, 2001). 
Genes encoding highlighted proteins have been found to be mutated or amplified in human cancer (blue). (C) 
Phosphorylation status of ERK1/2 (pERK1/2) in total and cytoplasmic extracts of the indicated genotypes of MEFs. (D) 
Analysis of ERK1/2 activation upon 20 minutes of FBS stimulation (20%) in the presence or absence of the MEK inhibitor 
PD98059 (40 µM). Before growth factor stimulation, cells were starved for 1.5 hours. In the Western immunoblots of 
(A), (C) and (D), GAPDH, caspase-3 and HSP90 were used as loading control; in (C) CyP-D was used as a mitochondrial 
marker. 
The absence of neurofibromin deregulates different signaling pathways (Fig. 3.1B). We 
investigated whether the Ras-MEK-ERK cascade was affected by Nf1 deletion by analyzing 
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the expression level of the active form of ERK1/2 (the phosphorylated form, pERK1/2). 
We found that heterozygous and homozygous MEFs for Nf1 deletion displayed an 
increase in ERK activation that was more pronounced in knock-out cells (Fig. 3.1C). These 
differences could be better highlighted if cells were kept in serum-free medium followed 
by FBS stimulation indicating that, after activation, Ras cannot be readily turned off if 
neurofibromin is absent; moreover, treatment with the inhibitor PD98059, which acts on 
the kinase upstream to ERK (MEK), was able to partially prevent ERK activation (Fig. 3.1D). 
3.2.2. Nf1 deletion induces tumorigenic properties in MEFs 
It has been previously shown that mice in which the Nf1 gene was selectively turned off in 
Schwann cells require a heterozygous environment for the Nf1 locus in order to develop 
neurofibromas (Zhu et al., 2002); however, the role of Nf1 knock-out fibroblasts in 
neurofibroma development has never been ruled out. Therefore, we decided to 
investigate the possible tumorigenic properties of MEFs upon Nf1 deletion. To this aim 
we performed a soft agar assay, an in vitro tumorigenic assay in which cells are 
embedded in an agar matrix; only transformed cells can grow in an anchorage-
independent way and form colonies, as they become capable of escaping anoikis cell 
death signals. As shown in Figure 3.2A, Nf1-/- MEFs are able to form colonies when 
embedded in an agar matrix; this indicates that neurofibromin loss is sufficient to induce 
a tumorigenic potential in these cells. Interestingly, the colony forming capability is 
abrogated when cells are treated with the MEK inhibitor PD98059, suggesting that the 
Ras-MEK-ERK pathway plays a key role in conferring tumorigenic potential to MEFs that 
do not have neurofibromin (Fig. 3.2B). We excluded toxic effects of the inhibitor used as it 
did not induce death of cells kept in the same growing conditions used for the soft agar 
assay (Fig. 3.2C). Moreover, the ability of Nf1-/- cells treated with PD98059 to form 
colonies was not a matter of time, since wild-type MEFs are not able to form colonies 
even after a longer (one month) period of incubation in soft agar (data not shown). 
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Figure 3.2. Absence of Nf1 promotes in vitro tumorigenesis of MEFs. (A) Colony formation of cells embedded in soft 
agar matrix. Representative areas showing colony growth are reported. (B) Total colony area at the 23
th
 experimental 
day with 2% serum in the presence or absence of the inhibitor PD98059 (40 µM). (C) Cell survival upon treatment for 3 
weeks with PD98059 (40 µM) of cells grown at 2% FBS. 
We have also tested the in vivo tumorigenic properties of wild-type and knock-out cells; 
to this purpose, MEFs of the two genotypes have been injected subcutaneously into both 
flanks of nude mice in the presence of Matrigel, a mixture of compounds that mimics the 
extracellular matrix. Growth was monitored and we observed that only cells without 
neurofibromin were able to form a tumor mass within a month from the injection (Fig. 
3.3A and B). Interestingly, we extracted the cells from the tumors and put them back in 
culture, finding that the cells obtained ex vivo did not express neurofibromin. This 
indicates that the tumor mass is fully formed by injected cells (Fig.3.3C). 
 
Figure 3.3. Absence of Nf1 promotes in vivo tumorigenesis of MEFs. (A) Kinetics of tumor growth in nude 
mice after subcutaneous injection of MEFs with a Matrigel bolus. (B) Representative tumor grown from Nf1
-
/-
 MEFs. (C) Neurofibromin expression in wild-type and knock out MEFs and in 6 cell samples obtained ex 
vivo from tumors grown from Nf1
-/-
 MEFs. Calnexin was used as a loading control. 
We thus observed that Nf1 loss induces tumorigenic properties in fibroblasts. Until now it 
was believed that only Schwann cells acquire tumorigenic properties in neurofibromas 
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following Nf1 LOH, whereas fibroblasts and other cell types would only provide 
environmental cues for neoplastic progression. These data suggest that fibroblasts could 
directly take part in neurofibroma development; this observation could be extremely 
important for the comprehension of neurofibroma onset and growth, and needs further 
investigation. 
3.2.3. Loss of Nf1 strongly impacts on cell metabolism 
Remodeling of energy metabolism is a recognized hallmark of cellular transformation that 
supports the sustained proliferation of cancer cells under conditions that restrict normal 
cell growth. It has been reported that oncogenic Ras is characterized by a decrease in 
glucose utilization through the TCA cycle and an enhanced glucose uptake (Chiaradonna 
et al., 2006). Therefore, we decided to investigate whether inactivation of the Ras 
regulator neurofibromin also affects cell metabolism. 
To this purpose, we investigated mitochondrial respiration using an Extracellular Flux 
Analyzer (Seahorse Bioscience) that allows the measurement of the oxygen consumption 
rate (OCR) in adherent cells both in basal condition and upon treatment with several 
compounds. We found that neurofibromin loss markedly reduced basal respiration in 
unstimulated cells (Fig. 3.4A); furthermore, the fraction of oxygen consumption coupled 
to ATP synthesis, which was calculated by adding the ATP synthase blocker oligomycin, 
was also lower in cells without neurofibromin (Fig. 3.4A, blue and red traces for wild-type 
and knock-out cells, respectively). Addition of low concentrations of the uncoupler FCCP 
is able to stimulate maximal respiration, another important mitochondrial parameter that 
can be used to uncover defects or modulations of the respiratory function. Maximal 
respiration achieved by knock-out cells was lower compared to the wild-type counterpart, 
indicating that neurofibromin loss decreases the respiratory capacity of mitochondria. In 
order to exclude possible toxic effects of FCCP treatment in combination with ATP 
synthase inhibition, we added the uncoupler in the presence or absence of oligomycin 
(Fig. 3.4A); however, we observed that Nf1-/- cells display a very low stimulation of 
respiration, even in the absence of oligomycin, which could not be improved by increasing 
the concentration of the uncoupler. The comparison between the two cell lines is striking 
as, unlike wild-type cells, Nf1-/- MEFs already utilize almost their maximal respiratory 
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capacity under basal conditions, an arrangement implying that any additional ATP 
requirement must be provided by glycolysis. Additions of the ETC inhibitors rotenone and 
antimycin A almost fully abolished the OCR, indicating that the respiration recorded was 
of mitochondrial origin (Fig. 3.4B). 
The differences in mitochondrial respiration that we have observed could be due to 
differences in cell number. To exclude this possibility, OCR data were normalized both for 
the cell number and the protein content. Moreover, changes in mitochondrial mass 
between the two cell types could affect OCR results. However, when the mitochondrial 
mass was evaluated by staining the cells with NAO, a fluorescent probe that binds the 
mitochondrial lipid cardiolipin, we detected comparable levels of mitochondrial mass in 
the two cell types (Fig. 3.4C). 
 
Figure 3.4. Nf1 deletion lowers mitochondrial respiration. (A) Representative traces of oxygen consumption rate (OCR) 
experiments performed on monolayers of living MEFs in basal condition and upon addition of the ATP synthase 
inhibitor oligomycin (blue and red traces for Nf1
+/+
 and Nf1
-/-
, respectively) or medium (light blue and orange for Nf1
+/+
 
and Nf1
-/-
, respectively), and of increasing concentration of the uncoupler FCCP.  (B) Representative traces of OCR 
measurements performed on Nf1
+/+
 (light blue trace) and Nf1
-/-
 (orange trace) MEFs. Subsequent additions of 
oligomycin, FCCP, the ETC complex I inhibitor rotenone and the ETC complex III inhibitor antimycin A are reported. (C) 
Measurement of mitochondrial mass by mean fluorescence intensity of NAO-stained MEFs expressed as ratio to values 
of wild-type cells. 
Even though the mitochondrial respiration was strikingly decreased in Nf1-/- cells, their 
mitochondria were polarized similarly to the wild-type counterpart, indicating that they 
were functional (Fig. 3.5A). Moreover, we could not identify remarkable differences in 
mitochondrial distribution or morphology under standard growing conditions (Fig. 3.5B). 
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Figure 3.5. Upon Nf1 deletion mitochondrial membrane potential and morphology do not change. (A) Measurement 
of mitochondrial membrane potential by mean fluorescence intensity of TMRM-stained MEFs. (B) Epifluorescence 
microscopy images showing mitochondrial morphology of TMRM-stained MEFs. 
In addition to OCR, these experiments allowed to monitor the extracellular acidification 
rate (ECAR), which is mainly caused by lactate efflux from the cells and is therefore 
proportional to the rate of conversion of pyruvate to lactic acid. Hence, the ECAR 
increases when the glycolityc flux is diverted from entering the TCA cycle, which can be 
due to an increase in glycolytic activity, a decrease in the rate of TCA, or both. 
Consistently with OCR measurements, the ECAR achieved upon addition of glucose was 
higher in knock-out cells compared to wild-type cells (Fig. 3.6A); as the ECAR was fully 
inhibited by 2-Deoxy-D-glucose (2-DG), an inhibitor of hexokinase, we concluded that 
cells depleted of Nf1 are more glycolytic. Furthermore, we investigated the amount of 
ATP that is produced by glycolysis. To this aim, we kept cells in the absence of glucose in 
combination with the glycolytic inhibitor 5-thio-glucose (5TG) in order to completely 
repress the glycolytic pathway (Fig. 3.6B). The drop in ATP levels detected upon glycolysis 
inhibition was higher in Nf1-/- cells compared to wild-type MEFs, indicating that cells 
depleted of Nf1 rely on glycolysis to synthesize ATP more than their wild-type 
counterparts. Nevertheless, we could not appreciate significant differences in the total 
ATP content between the two cell lines (data not shown) indicating that knock-out cells 
do not suffer of energy depletion. 
These observations are in line with previous reports describing a metabolic shift toward 
glycolysis in cells with oncogenic hyper-active Ras (Chiaradonna et al., 2006; Hu et al., 
2012); in our study, the absence of neurofibromin, a Ras negative regulator, leads to a 
similar phenotype, suggesting that deletion of Nf1 gene impacts on cell metabolism 
mainly acting through the Ras signaling pathway. 
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Figure 3.6. Nf1 deletion induces glycolytic metabolism. (A) Representative traces of extracellular acidification rate 
(ECAR) experiments performed on monolayers of living MEFs Nf1
+/+
 (light blue trace) and Nf1
-/-
 (orange trace). 
Subsequent additions of glucose, the ATP synthase inhibitor oligomycin, the glycolysis inhibitor 2-Deoxy-D-glucose (2-
DG) and medium were carried out. (B) ATP levels were measured under standard culture conditions or upon glucose 
depletion (2 hours) in the presence or absence of the hexokinase inhibitor 5-thio-glucose (5TG). 
3.2.4. Nf1 deletion leads to a modulation of the RC complex I (NADH 
dehydrogenase) 
Variations in OCR could result from several mechanisms of respiratory chain regulation, 
among which differences in synthesis/degradation rates of RC proteins, changes in the 
assembly/stability of RC complexes or super-complexes and regulation by post-
translational modifications. In order to investigate these possibilities, we started from the 
analysis of the expression level of different proteins of the respiratory chain complexes. 
Interestingly, complex I (NADH dehydrogenase) was affected by Nf1 loss, as the 
expression of its subunits NDUFSB8 and Grim19 was lowered in Nf1-/- cells; instead, 
expression of other complexes did not change between the two cell types (Fig. 3.7A). As 
complex I is a huge multimer composed by several subunits, we wondered whether the 
decrease in the expression of the subunits that we have analyzed could impact on the 
overall amount of complex I assembled in mitochondria. To answer this question, we 
extracted single ETC complexes from isolated mitochondria and performed an 
electrophoresis under native conditions (blue native polyacrylamide gel electrophoresis, 
BN-PAGE) (Wittig and Schagger, 2008). This technique is used for the isolation of protein 
complexes from biological membranes in order to estimate their native protein masses; 
furthermore, it can be applied to identify physiological protein-protein interactions (see 
3.2.6 section). Separated complexes were stained with Coomassie Blue G-250, which 
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revealed a decrease in the amount of the band corresponding to complex I. Native 
complexes were recovered from gel by cutting the corresponding bands and were 
subjected to a second dimension electrophoresis performed in denaturing conditions 
(SDS-PAGE); this allowed separation of complexes into single protein components, which 
were therefore identified by Western immunoblotting (Fig. 3.7B). In accord with SDS-
PAGE data, we found a decrease in Complex I components, whereas the amount of other 
respiratory chain complexes as complex II, III and V was not affected by Nf1 loss. In 
accordance to this data, the rotenone-sensitive NADH-CoQ oxidoreductase activity 
measured in isolated mitochondria was remarkably lower in Nf1-/- cells compared to wild-
type (Fig. 3.7C). 
These data indicate that Nf1 loss leads to a modulation of mitochondrial respiration 
mainly due to a decrease in complex I level that thus down-regulates its activity. We could 
not reveal modulation of the expression level of other RC complexes but we cannot 
exclude alterations of their activity achieved through different mechanisms (see section 
3.2.6). 
 
Figure 3.7. Nf1 deletion is accompanied by a decrease in the RC complex I (NADH dehydrogenase). (A) Analysis of 
mitochondrial protein level of different subunits of respiratory chain complexes. Calnexin was used as a loading control. 
(B) Isolated mitochondria were subjected to blue native gel electrophoresis to separate ETC complexes. Bands 
corresponding to complex I, III and V were excised, run on a SDS-PAGE and probed with anti NDUFB8 and Grim19, anti 
Core2, and anti α antibodies in order to detect subunits of complex I, III and V, respectively. (C) Complex I (rotenone-
sensitive NADH-CoQ oxidoreductase) activity measured in isolated mitochondria. Values were normalized for citrate 
synthase (CS) activity and shown as ratio to wild-type cells. 
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3.2.5. ERK activation is responsible for RC complex I modulation 
The signaling cascades regulated by neurofibromin can affect gene transcription, by 
regulating key transcription factors such as Myc, Elk1, Fos, and Ets, or modulate the 
synthesis or post-translational modification of a wide variety of proteins. 
Given the strong impact of Nf1 loss on the expression level of complex I subunits, we 
wondered whether this could be due to the hyper-activation of ERK. In order to test this 
hypothesis, we prevented ERK activation by inhibiting MEK with PD98059 for 3 days. In 
accord with this hypothesis, we found that this treatment affected the expression of 
Grim19, a subunit of complex I, but not the expression of components of other RC 
complexes, such as CII and CV (Fig. 3.8A). Moreover, we confirmed complex I modulation 
also by analyzing the expression level of other of its subunits in isolated mitochondria 
(Fig. 3.9B). This effect is present in both wild-type and knock-out cell lines as under basal 
condition a fraction of ERK was in the phosphorylated form; however, the increase in 
complex I expression was stronger in Nf1-/- cells. 
 
Figure 3.8. ERK inhibition specifically modulates RC complex I expression. (A) Expression level of different subunits of 
RC complexes upon treatment for 3 days with the MEK inhibitor PD98059 (40 µM) which prevents ERK activation 
(pERK1/2) in total lysates. (B) Expression level of different subunits of RC complex I in mitochondrial lysates following 3 
days PD98059 (40 µM) treatment. Calnexin was used as a loading control. 
Hereafter, we investigated whether the treatment with PD98059 also affected the 
amount of assembled complex I, in order to understand if the increase in the subunits 
that we have analyzed actually results in a modulation of the entire RC complex I. 
Performing a blue native gel electrophoresis under basal conditions or after a 3 days ERK 
inactivation (Fig. 3.9B), we observed that ERK inhibition increased the quantity of 
assembled complex I; as observed before with experiments on the single subunits, also 
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the assembly of other RC complexes did not vary following ERK inhibition. Moreover, ERK 
inactivation leaded to an increase in complex I activity, as measured by the rotenone-
sensitive NADH-CoQ oxidoreductase activity in isolated mitochondria of control and 
treated cells (Fig. 3.9C). 
 
Figure 3.9. Inhibition of ERK increases the amount and activity of RC complex I. (A) Blue native gel electrophoresis of 
mitochondria isolated from cells treated or not for 3 days with PD98059 (40 µM). Bands corresponding to complex I, III 
and V were excised, run on a SDS-PAGE and probed with anti NDUFS1, NDUFS3, NDUFB8 and Grim19 antibodies to 
detect complex I, and anti Core2 and anti α antibodies to detect complex III and V, respectively. (B) Expression level of 
active and total ERK in total lysates of cells used in (A). Calnexin was used as a loading control. (C) Complex I (rotenone-
sensitive NADH-CoQ oxidoreductase) activity measured in isolated mitochondria from cells treated or not for 3 days 
with PD98059 (40 µM). Values were normalized for citrate synthase (CS) activity and shown as ratio to wild-type 
untreated cells. 
These results indicate that the activation level of the kinase ERK plays an important role in 
determining specifically the expression level of complex I subunits; preventing ERK 
activation was able to modulate complex I amount and activity, and the range of variation 
detected was dependent on the initial phosphorylation status of ERK. 
3.2.6. Nf1 loss results in modulation of RC complex II (succinate dehydrogenase) 
activity 
We then investigated whether the inhibition of respiration of Nf1-/- cells could also 
depend on changes in the activity of other RC complexes, beside complex I. Previous work 
from our laboratory has demonstrated that inhibition of SDH activity can contribute to 
the tumorigenic process by modulating HIF1 transcriptional activity and the redox 
equilibrium of the cell (Sciacovelli et al., 2013). We therefore focused on the succinate-
CoQ reductase (SQR) enzymatic activity of complex II (succinate dehydrogenase) which 
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was decreased in Nf1-/- cells compared to wild-type MEFs (Fig. 3.10A). As described before 
(see Fig. 3.7A), the expression level of complex II did not vary in the absence of 
neurofibromin. Therefore, we explored the possibility that SDH activity could be 
regulated at a post-transcriptional level by the Ras-MEK-ERK pathway. Indeed, we found 
that a fraction of ERK was localized inside mitochondria (Fig. 3.10B) in accord with data 
obtained in our laboratory on different tumor cell models (Rasola et al., 2010); 
interestingly, even though the amount of ERK found in mitochondria was similar in all 
three genotypes, Nf1-/- cells showed a remarkable increase in the activation status of 
mitochondrial ERK in comparison to wild-type and Nf1+/- MEFs. Notably, when we excised 
the BN-PAGE band corresponding to SDH complex and run it on a SDS-PAGE, we detected 
an unprecedented co-migration between complex II, active ERK and TRAP1 (Fig. 3.10C).  
 
Figure 3.10. Modulation of RC complex II (succinate dehydrogenase) following Nf1 deletion. (A) Succinate-CoQ 
reductase (SQR) enzymatic activity of complex II in isolated mitochondria. Values were normalized for citrate synthase 
(CS) activity and shown as ratio to wild-type cells. (B) Analysis of the mitochondrial fraction of active ERK. Isolated 
mitochondria were subjected to partial trypsinization to get rid of non-mitochondrial contaminants. CyP-D was used as 
loading control; Calnexin was used as extra-mitochondrial marker. (C) Isolated mitochondria were subjected to blue 
native gel electrophoresis to separate ETC complexes. Bands corresponding to complex II were excised, run on a SDS-
PAGE and probed with anti SDHB (for complex II detection), anti pERK1/2, and anti TRAP1 antibodies. (D) Expression 
level of TRAP1 and ERK2 in total lysates of MEFs. CyP-D was used as a loading control. 
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The mitochondrial chaperone TRAP1, which is induced in most tumor types, was recently 
reported to be required for neoplastic growth as it confers transforming potential to non-
cancerous cells (Sciacovelli et al., 2013). Indeed, as described in section 1.3.3 of 
Introduction, it was found that TRAP1 binds to and inhibits succinate dehydrogenase, 
promoting tumorigenesis by priming the succinate-dependent stabilization of the pro-
neoplastic transcription factor HIF1α, independently of hypoxic conditions. We 
investigated the expression level of TRAP1 in the three genotypes finding that they were 
comparable (Fig. 3.10D). Therefore, differences in the interaction between complex II, 
ERK and TRAP1 between wild-type and knock-out cells could not be explained by diversity 
in the expression level of these proteins; and if the assembly of this multimeric complex 
down-regulates SDH activity in Nf1-/- cells, this could occur by post-translational 
modifications affecting the catalytic site of SDH.  
3.2.7. TRAP1 plays a key role in the tumorigenic properties of MEFs depleted of 
neurofibromin 
Hence, we decided to investigate whether the different co-migration between complex II 
and TRAP1 observed in MEFs with or without neurofibromin could explain the difference 
in complex II activity. We down-regulated TRAP1 levels by RNA interference (Fig. 3.11A) 
and analyzed the SQR enzymatic activity in isolated mitochondria of control and 
interfered cells; however, we could not find differences in complex II activity upon TRAP1 
modulation (Fig. 3.11B). Consistently, TRAP1 down-regulation did not affect basal 
respiration in none of the two cell types; nevertheless, we surprisingly found that TRAP1 
interference increased maximal respiration in Nf1-/- but not in wild type cells (compare 
the traces in Fig. 3.11C after uncoupling with FCCP). These results indicate that Nf1-/- cells 
display a respiratory reservoir upon TRAP1 down-regulation, suggesting that this 
chaperone exerts an inhibitory effect on mitochondrial respiration which can be unveiled 
only under certain conditions (FCCP stimulation). 
In addition to this, given the important role of TRAP1 in the tumorigenic process of 
different cancer cell models, we examined whether it plays a similar role also in cells that 
are depleted of Nf1. To test this hypothesis, we performed an in vitro tumorigenic assay, 
finding that TRAP1 interference abrogates the ability of Nf1-/- MEFs to form colonies in 
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soft agar matrix. These observations point to a principal role of TRAP1 in the tumorigenic 
process of cells depleted of Nf1 gene; nevertheless, it remains to be established whether 
it works primarily through inhibition of succinate dehydrogenase activity and/or through 
other mechanisms. 
 
Figure 3.11. TRAP1 down-regulation modulates the tumorigenic properties of Nf1
-/-
 MEFs. (A) Expression level of 
TRAP1 upon RNA interference. Prohibitin and Calnexin were used as loading controls. (B) Succinate-CoQ reductase 
(SQR) enzymatic activity of complex II on isolated mitochondria of Nf1
+/+
 and Nf1
-/-
 MEFs upon TRAP1 knock-down. 
Values were normalized for citrate synthase (CS) activity and shown as ratio to wild-type cells. (C) Representative traces 
of OCR measurements performed on monolayers of living MEFs Nf1
+/+
 (blue trace) and Nf1
-/-
 (trace) transfected with a 
shRNA against TRAP1 (light blue and red traces, respectively). Subsequent additions of the uncoupler FCCP, the ETC 
complex I inhibitor rotenone and the ETC complex III inhibitor antimycin A were carried out. (D) Total colony area at the 
23
th
 experimental day with 2% serum of Nf1
+/+
 and Nf1
-/-
 MEFs upon TRAP1 down-regulation. 
3.2.8. OXPHOS modulation and cell death resistance: is there a connection in Nf1-
deficient MEFs? 
Our study has shown that deletion of Nf1 gene in mouse embryonic fibroblasts leads to 
metabolic rearrangements in favor of a glycolytic metabolism; moreover, we have 
observed that Nf1 loss in these cells is able to promote neoplasm growth. Still, it remains 
to be elucidated if metabolic reprogramming has a direct link to tumorigenesis. A possible 
connecting point is the modulation of the PTP opening as a major player in cell death 
susceptibility. 
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We have studied PTP opening using the Ca2+ retention capacity assay, which allows the 
measurement of the amount of Ca2+ threshold needed to open the channel; 
consequently, the number of Ca2+ pulses which are taken up by mitochondria is used as 
indication of the susceptibility of the PTP to opening. We observed that Nf1-/- MEFs take 
up more Ca2+ before pore opening, which indicates that the PTP of knock-out cells is more 
resistant to induction (Fig. 3.12A). The reasons for such a modulation could be of several 
origins; even so, we detected more HK II bound to mitochondria of cells without 
neurofibromin (Fig. 3.12B), therefore we would like to investigate whether they are more 
sensitive to HK displacing agents. 
 
Figure 3.12. Resistance to PTP opening and cell death of Nf1-deficient cells. (A) PTP opening was measured with the 
whole-cell Ca
2+
 retention capacity assay (CRC). Ca
2+
 Green-5N fluorescence is reported as arbitrary units on the y axis. 
(B) Analysis of the mitochondrial fraction of active HK II. Isolated mitochondria were subjected to trypsinization at 4°C 
for 1 hour at a mitochondria:trypsin ratio of 35:2 (w/w). CyP-D, TRAP1 and Prohibitin were used as loading controls; 
Caspase-3 and Calnexin were used as extra-mitochondrial markers. (C) Cell viability of cells treated with cisplatin (25 
and 50 µM) for 16 hours in the presence or absence of NAC (500 µM). Values were normalized for cell viability of 
untreated cells. 
Neurofibromin-deficient MEFs have been reported to be more resistant than 
neurofibromin-expressing cells to apoptosis suggesting that neurofibromin might act as a 
sensitizer of apoptosis (Shapira et al., 2007). Moreover, the resistance to apoptosis 
caused by neurofibromin deficiency was not attributable to an inherent enhancement of 
the apoptotic threshold due to changes in the expression levels of key apoptotic proteins 
(e.g., Bcl-2 family and caspases) suggesting that a more direct pro-apoptotic action of 
neurofibromin could be lacking. It is known that an unbalance in reactive oxygen species 
(ROS) plays an important role in committing cells to death and the respiratory chain is one 
of the major regulators of ROS production (Lemarie and Grimm, 2011); it follows that 
changes in the functionality of OXPHOS activity could affect ROS generation and the 
ensuing PTP induction and cell death. 
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We measured cell survival upon treatment with the chemotherapeutic drug cisplatin 
finding that Nf1-deficient cells are more resistant to death (Fig. 3.12C). As the toxicity of 
this drug was prevented by N-acetyl cysteine (NAC) we could hypothesize that it exerts a 
pro-oxidant action which could be of different entity in the two cell lines. It has been 
recently shown by our group that the rapid rise in ROS levels prompted by cisplatin 
treatment is strictly regulated by complex I (Ciscato et al., 2013); this points our interest 
toward the possible connection between cell death escape of Nf1-/- cells and the 
modulation of OXPHOS activity. Therefore, we would like to investigate the cell death 
sensitivity of Nf1 knock-out cells to treatments with ROS-inducing agents that mainly 
target complex I (e.g., EM20-25, AUL12) (Chiara et al., 2012). 
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4. DISCUSSION 
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In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative 
phosphorylation to supply the energy needed for cellular processes, most cancer cells 
instead rely on aerobic glycolysis, a phenomenon termed ‘the Warburg effect’ (Vander 
Heiden et al., 2009). Therefore, the attention toward tumor metabolism rewiring has 
risen progressively in the last years and an increasing body of research indicates that the 
capability to modify, or reprogram, cellular metabolism is crucial to most effectively 
support neoplastic proliferation (Hanahan and Weinberg, 2011). Beside this, given the 
principal role of mitochondria in modulating both bioenergetic processes and the cell 
death machinery, a possible connection between the metabolic adaptations and the 
capability to escape cell death that characterize tumor cells starts to stand out. Indeed, 
mitochondrial respiration is strongly connected to cell death induction for several 
reasons: first of all the respiratory chain is the major source for the production of ROS, 
which play an important role in determining cell fate; moreover, the functionality of 
OXPHOS contributes to the establishment of the threshold level for PTP opening so that, 
when a dysfunction in respiratory chain complexes is present, the PTP is more sensitized 
to inducing signals (Porcelli et al., 2009). 
We have reported in this study that cells forced to glycolytic metabolism due to complete 
mtDNA depletion (ρ0 cells) acquire typical feature of cancer cells. Indeed, similar to tumor 
cells (Chiara et al., 2008; Mathupala et al., 2006) ρ0 cells are characterized by a relocation 
of the glycolytic enzyme HK II to the mitochondrial surface where it contributes to the 
maintenance of the PTP in the closed state, thus increasing the threshold level for cell 
death induction. Indeed, these cells are more sensitive to HK II detaching agents 
(clotrimazole and a HK II-derived peptide), supporting a model by which the protective 
role of mitochondrial HK II is caused by its inhibition of PTP opening. In addition to this, 
we have detected a constitutive activation of the ERK-GSK3 signaling pathway that 
converge on mitochondria of ρ0 cells in order to maintain CyP-D in a dephosphorylated 
state, thus enhancing the threshold for PTP induction. Again, these data are in accord 
with what was reported for neoplastic cells (Rasola et al., 2010). Our study has shown 
that ρ0 cells can undergo a CsA-sensitive permeability transition, thus forcing these cells 
to set up mechanisms of PTP resistance as a death-escaping strategy. Interestingly, 
regulation of PTP by mitochondrial HK II is a mechanism strictly interconnected with the 
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metabolic status of these cells, suggesting that the sole rewiring of cell metabolism from 
OXPHOS to aerobic glycolysis could be sufficient for the modulation of one of the main 
actors of cell death machinery: the PTP. Furthermore, this is also a target of signaling 
cascades that are often deregulated in cancers, and this brings to the second part of my 
dissertation. 
Metabolic pathways active in proliferating cells are directly controlled by signaling 
cascades involving known oncogenes and tumor suppressor genes (Vander Heiden et al., 
2009). Indeed, the majority of oncogenic mutations can affect multiple hallmark 
capabilities of cancer cells (e.g., proliferative signaling, energy metabolism, angiogenesis, 
invasion, and survival) (Hanahan and Weinberg, 2011). Recent evidences show that 
oncogenic signaling pathways, such as the Ras-ERK transduction axis, have mitochondrial 
branches. This suggests that deregulated kinase signaling in mitochondria could be 
directly responsible for tumor metabolic rewiring. In this conceptual framework we have 
investigated whether the absence of neurofibromin, which hyper-activates the Ras-ERK 
pathway and is linked to tumor development in individuals affected by Neurofibromatosis 
type 1, is able to modify mitochondrial bioenergetics, thus contributing to growth 
advantage and cell death escape of neoplastic cells.  
We have observed that loss of neurofibromin elicits tumorigenic properties in MEFs both 
in vitro and in vivo; indeed, these cells acquire the capability to grow in an anchorage-
independent way and form tumors when injected into nude mice. The up-regulation of 
the Ras-MEK-ERK pathway is of fundamental importance for the pro-tumorigenic 
properties gained upon Nf1 deletion as its inactivation by the MEK inhibitor PD98059 fully 
prevents neoplastic growth. Our observations are important in the frame of the cellular 
heterogeneity of neurofibromas, the most common tumor type that affects NF1 patients. 
There is no doubt that neurofibromin loss in Schwann cells play a principal role in tumor 
formation (Zhu et al., 2002); nevertheless, fibroblasts could also participate to this 
process, not only as bystander cells that modulate signaling circuitries of Schwann cells, 
but also as transformed cells by themselves. This possibility is strengthen by the fact that 
neoplastic transformation (e.g., neurofibromin inactivation) of NCSCs or non-neuronal 
restricted nerve progenitors could potentially lead to clonal tumors containing both 
Schwann cells and fibroblasts (Joseph et al., 2004). 
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Even though the growth advantages of cells with inactivated neurofibromin have been 
previously described (Muir et al., 2001; Wu et al., 2005), their metabolic characterization 
has not been enquired so far. On the contrary, several studies have shown important 
metabolic alterations in cells with oncogenic Ras (see section 1.2.1.5 of Introduction). We 
found that Nf1 loss in MEFs leads to a metabolic shift toward glycolysis with a strong 
decrease in mitochondrial respiration. This is principally achieved through a modulation 
of RC complex I; in detail, there is a decrease in the expression level of complex I subunits 
with a consequent impairment of its activity. Interestingly, we observed that these 
changes are dictated by the up-regulation of the kinase ERK, which is able to impact on 
the expression level of complex I subunits. As the transcriptional profiling of oncogenic 
Ras-expressing cells was found strongly altered (Gaglio et al., 2011), we presume that, in a 
parallel way, the metabolic alterations detected following Nf1 deletion could also be 
explained by changes at the level of transcription. Indeed, beside the important function 
of ERK in regulating the phosphorylation status of several transcription factors, it has 
been very recently reported that it regulates the translocation event of PKM2 to the 
nucleus where it modulates gene transcription, thus contributing to the Warburg effect 
(Yang et al., 2012). 
We also detected a decrement in RC complex II activity following Nf1 deletion which is 
not paralleled by changes in protein level of its subunits; nonetheless, we found that in 
Nf1-/- MEFs complex II strongly interacts with the active mitochondrial fraction of ERK and 
the chaperone TRAP1. As TRAP1 has been shown to promote neoplastic growth through 
inhibition of succinate dehydrogenase (Sciacovelli et al., 2013), we silenced its expression 
by RNA interference, finding that the tumorigenic properties of Nf1-/- MEFs were 
abolished. These results suggest that inhibition of mitochondrial respiration following 
neurofibromin loss could prompt neoplastic transformation in a TRAP1-dependent 
manner, providing an unprecedented connection between metabolic changes and 
tumorigenesis in a NF1 model; therefore, inhibition of TRAP1 in neurofibromin-deficient 
cells could be a therapeutic strategy against cancer growth; however, it remains to be 
determined if TRAP1 triggers tumorigenesis through the already reported mechanism of 
HIF1α stabilization due to succinate accumulation and/or thanks to additional functions 
(e.g., oxidative stress resistance) (Costantino et al., 2009). In fact, TRAP1 down-regulation 
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does not affect complex II activity in our model; yet, it stimulates maximal respiration in 
cells without neurofibromin. 
In conclusion, even if it is becoming increasingly clear that oncogenic deregulation of the 
Ras signaling pathway prompts a variety of bioenergetic changes, little is known about 
the role played by metabolic adaptations in NF1 tumorigenesis. We have shown that Nf1-
deficient cells display a remarkable rewire of cellular bioenergetics which could 
potentially participate in a determinant manner to the tumorigenic process. We will 
further examine the mechanisms that are responsible for the neoplastic growth 
investigating the pathways that are shaped by mitochondrial function (e.g., HIF1α 
stabilization, PTP modulation). 
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GSK3βRespiratory complexes are believed to play a role in the function of the mitochondrial permeability transition
pore (PTP), whose dysregulation affects the process of cell death and is involved in a variety of diseases, in-
cluding cancer and degenerative disorders. We investigated here the PTP in cells devoid of mitochondrial
DNA (ρ0 cells), which lack respiration and constitute a model for the analysis of mitochondrial involvement
in several pathological conditions. We observed that mitochondria of ρ0 cells maintain a membrane potential
and that this is readily dissipated after displacement of hexokinase (HK) II from the mitochondrial surface by
treatment with either the drug clotrimazole or with a cell-permeant HK II peptide, or by placing ρ0 cells in a
medium without serum and glucose. The PTP inhibitor cyclosporin A (CsA) could decrease the mitochondrial
depolarization induced by either HK II displacement or by nutrient depletion. We also found that a fraction of
the kinases ERK1/2 and GSK3α/β is located in the mitochondrial matrix of ρ0 cells, and that glucose and
serum deprivation caused concomitant ERK1/2 inhibition and GSK3α/β activation with the ensuing phos-
phorylation of cyclophilin D, the mitochondrial target of CsA. GSK3α/β inhibition with indirubin-3′-oxime
decreased PTP-induced cell death in ρ0 cells following nutrient ablation. These ﬁndings indicate that ρ0
cells are equipped with a functioning PTP, whose regulatory mechanisms are similar to those observed in
cancer cells, and suggest that escape from PTP opening is a survival factor in this model of mitochondrial dis-
eases. This article is part of a Special Issue entitled: 17th European Bioenergetics Conference (EBEC 2012).
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The creation of cells depleted of mitochondrial DNA (mtDNA),
termed ρ0 cells [1,2], has been a major advance in the study and un-
derstanding of mtDNA diseases. The availability of ρ0 cells allowed
their repopulation with different mitochondrial genomes, and thus
provided an essential tool to deﬁne key pathogenic parameters such
as the degree of heteroplasmy and threshold levels of mutant mtDNA
[3,4]. ρ0 cells represent an extreme case of mitochondrial dysfunction
that has also attracted considerable interest in the ﬁelds of bioenerget-
ics and cell death [5–18], in particular about the intrinsic pathway to
apoptosis that is triggered by release of mitochondrial apoptogenicΔψm, mitochondrial membrane
thyl)-N,N,N’,N’-tetraacetic acid;
one; HK II, Hexokinase II; PTP,
ELNβA-GYGRKKRRQRRRG pep-
methyl ester
opean Bioenergetics Conference
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rnardi@bio.unipd.it
l rights reserved.proteins [19] and about the effector mechanisms of necrosis caused by
bioenergetic failure [20].
One candidate mechanism for the irreversible commitment to cell
death is the mitochondrial permeability transition pore (PTP), an inner
membrane cyclosporin (Cs) A-sensitive, high-conductance channel
whose opening causes mitochondrial depolarization and a variety of ef-
fects that depend on the PTP open time [21]. Whereas short open times
may take part in physiological Ca2+ signalling by providing mitochon-
dria with a fast Ca2+ release channel [22–26], longer openings lead to
rearrangement of the cristae and to matrix swelling and eventually
prompt outer membrane rupture followed by release of cytochrome c
andof other proapoptotic proteins (such asAIF, Smac/DIABLOand endo-
nuclease G) for which there is no selective release pathway in the outer
membrane [27].
Despite the crucial importance of PTP in cell biology and in the path-
ogenesis of a number of diseases [28], its molecular composition re-
mains an unsolved riddle. The activity of RC complexes and of ATP
synthase can inﬂuence the PTP, as ROS generated as a respiratory by-
product can elicit pore openings [29]. We have demonstrated that
the PTP modulator cyclophilin D (CyP-D) binds and inhibits the ATP
synthase [30] and that the activity of RC complex I contributes to setting
the threshold voltage for PTP opening [31], providing molecular and
conceptual bases for the existence of a functional interplay between
1861I. Masgras et al. / Biochimica et Biophysica Acta 1817 (2012) 1860–1866respiration and the PTP. Moreover, we have recently shown that PTP
opening plays a pathogenic role in two models of mitochondrial dis-
eases endowed with inactivation of RC complex I, i.e. HL180 cybrids
harboring two missense mutations causative of Leber Hereditary Optic
Neuropathy in the mtDNA ND6 gene [32,33], and the cell line XTC.UC1
(derived from a thyroid oncocytoma [34]) that bears a disruptive frame-
shift mutation in the mtDNA ND1 gene [35]. Nonetheless, whether
the PTP is involved in other mtDNA disease models is not known,
and a formal deﬁnition of the role played by RC complexes in PTP regu-
lation and molecular composition is still lacking.
Cells devoid of mtDNA also constitute a potential model for the
study of the bioenergetics of neoplasias, where mitochondrial respi-
ration is decreased and ATP is largely provided by inducing glycolysis
and uncoupling it from oxygen availability, theWarburg effect [36–38].
Thus, ρ0 cells can be considered as possessing an extreme “Warburg
phenotype”. Furthermore, reduction of mtDNA copy number was
reported in diverse types of tumors such as stomach, colon, lung [39],
hepatocellular [40], ovarian [41] and breast carcinomas [42] and astro-
cytomas [43]; mtDNA was also reported to affect angiogenesis, inva-
siveness [44,45] and resistance to death of tumor cells [15,46]. We
and others have observed that mitochondria from tumor cells display
an increased resistance to PTP opening as a death-escaping strategy,
and this is achieved both by deploying hexokinase (HK) II on the mito-
chondrial surface, where it maintains the PTP in a closed state through
a poorly deﬁned signal transduction cascade directed to matrix compo-
nents such as CyP-D [47]; and by constitutively inducing an ERK/GSK3
signalling pathway that maintains CyP-D in a dephosphorylated state,
thus enhancing the threshold for PTP induction [48,49].
In keepingwith these data, herewe observe that in human osteosar-
coma 206 ρ0 cells the PTP is induced both by HK II detachment from
mitochondria, and by modulation of an ERK/GSK3/CyP-D transduction
axis following glucose and serum depletion.2. Materials and methods
2.1. Materials, cell cultures and growth conditions
Tetramethylrhodamine methyl ester (TMRM) was from Molecular
Probes (Eugene, OR); FITC-conjugated annexin-V was from Boehringer
Mannheim (Indianapolis, IN); indirubin-3′-oxime and CsA were from
Calbiochem (San Diego, CA); cyclosporin H (CsH) was a generous
gift of Dr. Urs Ruegg, Geneva; all other chemicals were from Sigma
(Milan, Italy). Mouse monoclonal anti GSK-3α/β, Grim19, SDHA
and UQCRC1, goat polyclonal anti calnexin, HK II and VDAC1, and rab-
bit polyclonal anti ERK2, PARP and TOM20 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA); rabbit polyclonal anti phospho-
ERK1/2 (Thr202/Tyr204) and anti phospho GSK-3α/β (Ser21/9) and
rabbit monoclonal anti caspase-3 antibodies were from Cell Signaling
(Beverly, MA); mouse monoclonal anti phospho-Ser/Thr, CyP-D and
anti prohibitin antibodies were from Qiagen, Calbiochem, and Lab Vi-
sion (Fremont, CA), respectively; rabbit polyclonal anti AIF antibody
was from Exalpha Biologicals (Shirley, MA); the mouse monoclonal
OXPHOS antibody cocktail recognizing CI (NDUFB8), CII (SDHB), CIII
(core2), CIV (COXII) and CV (α) was from Mito-Sciences (Eugene,
OR). Peptides MIASHLLAYFFTELNβA-GYGRKKRRQRRRG (TAT-HK II)
and GYGRKKRRQRRRG-βA-EEEAKNAAAKLAVEILNKEKK (TAT-Ctrl)
were synthesized by a solid phase method using an automatized pep-
tide synthesizer (model 431-A, Applied Biosystems, Foster City, CA).
The human 143B osteosarcoma and the derived 206 ρ0 cell lines
were kindly provided by Lodovica Vergani (Department of Neurosci-
ences, University of Padova, Padova, Italy). Cells were grown in high
glucose (4500 mg/l) Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 10% fetal bovine serum, 4 mM L-glutamine, 110 mg/l sodi-
um pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin
in a humidiﬁed incubator at 37 °C with 5% CO2. Medium of ρ0 cellswas supplemented with 50 mg/l uridine, essential amino acids and
vitamins.
2.2. Mitochondrial membrane potential and cell death
Mitochondrial membrane potential (Δψm) was measured either by
epiﬂuorescence microscopy or by ﬂow cytometry (see below). For
epiﬂuorescence microscopy cells were seeded onto 24 mm-diameter
round glass coverslips and grown for 2 days in DMEM. Δψm was mea-
sured based on the accumulation of TMRM in the presence of CsH,
which inhibits the multidrug resistance pump but not the PTP [50,51].
Cells were incubated in bicarbonate- and phenol red-free DMEM
supplemented with 10 mM Hepes and 1.6 μM CsH and loaded with
20 nM TMRM for 30 min at 37 °C. At the end of each experiment, mito-
chondria were fully depolarized by the addition of 4 μMof the protono-
phore FCCP. Cellular ﬂuorescence images were acquired with an
Olympus IX71/IX51 inverted microscope equipped with a xenon light
source for epiﬂuorescence illumination and with a 12-bit digital cooled
CCD camera (Micromax, Princeton Instruments, Trenton, NJ). For detec-
tion ofﬂuorescence 568±25 nmbandpass excitation and 585 nm long-
pass emission ﬁlter settings were used. Images were collected every
3 min with an exposure time of 100 ms (6% illumination intensity)
using a 40×, 1.3 NA oil immersion objective (Olympus). Data were ac-
quired and analyzed using Cell R software (Olympus). Clusters of several
mitochondria were identiﬁed as regions of interest, and ﬁelds not con-
taining cells were taken as the background. Sequential digital images
were acquired every minute, and the average ﬂuorescence intensity of
all relevant regions was recorded and stored for subsequent analysis.
For FACS analysis cells were resuspended in 135 mM NaCl, 10 mM
Hepes, 5 mM CaCl2 and incubated for 15 min at 37 °C with TMRM
(20 nM) and CsH (1.6 μM) or with FITC-conjugated Annexin-V, to de-
tect mitochondrial membrane depolarization (reduced TMRM stain-
ing) or phosphatidylserine exposure on the cell surface (increased
FITC-conjugated Annexin-V staining) respectively. Changes in forward
and side light scatter were assessed at the same time to measure alter-
ations in cell dimension and granularity, respectively. Samples were
analyzed on a FACSCanto II ﬂow cytometer (Becton Dickinson, San
Diego, CA, USA). Data acquisition and analysis were performed using
FACSDiva software. Regions were designed on diagrams to evaluate
the percentage of cell subpopulations as indicated in Fig. 3.
2.3. Cell lysis, fractionation, western immunoblot analysis
Total cell extracts were prepared at 4 °C in 150 mM NaCl, 20 mM
Tris–HCl pH 7.4, 5 mM EDTA, 10% glycerol, 1% Triton X-100 in the
presence of phosphatase and protease inhibitors (Sigma). To prepare
mitochondrial extracts, cells were placed in isolation buffer (250 mM
sucrose, 10 mM Tris–HCl, 0.1 mM EGTA–Tris, pH 7.4) and homoge-
nized at 4 °C. Mitochondria were then isolated by differential centri-
fugation in mitochondrial isolation buffer. Unless otherwise stated,
mitochondria were treated with trypsin at 4 °C for 1 h at a mitochon-
dria:trypsin ratio of 35:1 (w/w). After trypsin inactivation with a pro-
tease inhibitor cocktail (Sigma), mitochondria were spun at 18,000×g
at 4 °C for 10 min. For immunoprecipitation, 4 mg of extracted pro-
teins per reaction was incubated with antibodies conjugated to pro-
tein A-Sepharose beads (Pharmacia, Pﬁzer, Cambridge, MA) at 4 °C
overnight. Negative controls were performed by incubating lysates
on beads in the absence of primary antibodies. Samples were separated
under reducing conditions on SDS-polyacrylamide gels and transferred
onto Hybond-C Extra membranes (Amersham). Primary antibodies
were incubated 16 h at 4 °C, and horseradish peroxidase-conjugated
secondary antibodies were added for 1 h at room temperature. Proteins
were visualized by enhanced chemiluminescence (Millipore). Densito-
metric analysis was performed with Quantity One software (Bio-Rad
Laboratories).
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Unless otherwise stated each experiment was repeated at least
three times. Data are presented as average±S.E. or, for clarity, as rep-
resentative experiments (see ﬁgure legends for details).3. Results
3.1. Characterization of ρ0 cells
In order to characterize the 206 ρ0 human osteosarcoma cell line,
we assessed the expression of a panel of respiratory chain (RC) sub-
units, whose assembly requires proteins encoded by mitochondrial
DNA (mtDNA) genes with the exception of RC complex II. As expected,
we found that 206 ρ0 cells were totally devoid of RC complexes I and IV,
whereas they displayed a level of nuclear-encoded RC proteins of RC II
and III and of the ATP synthase comparable to the parental 143B ρ+
cells (Fig. 1A).
We also monitored Δψm in situ by measuring cell accumulation of
TMRM. Under our loading conditions mitochondrial depolarization
corresponds to a decrease of mitochondrial ﬂuorescence, since the ac-
cumulated probe is still below the quenching threshold [52]. It shouldFig. 1. ρ0 cells display a mitochondrial membrane potential and upregulate HK II. A, immun
human osteosarcoma ρ+ cells and in 206 ρ0 cells. B, epiﬂuorescence microscopy images of ρ
the addition of 4 μM FCCP. C, immunoblot analysis of HK II expression in total cell extracts fr
HK II in ρ0 cells; the lanes refer to the cytosolic (Cyto) and to the mitochondrial fraction (M
Calnexin and Tom20 are used as loading controls in A and C; calnexin, PARP and caspase-3 a
purity of mitochondria in D; Tom20 and AIF are markers of the outer mitochondrial memb
matrix proteins.be noted that cells were also treated with CsH, which does not affect
the PTP but inhibits the multidrug resistance pump and therefore
normalizes cytosolic loading with TMRM, which is a substrate of the
pump and could therefore be extruded at rates that vary widely in
different cell types [50]. Both ρ+ and ρ0 osteosarcoma cells displayed
a punctuate pattern of TMRM labelling, which disappeared after
treatment with the uncoupler FCCP (Fig. 1B), thus conﬁrming that
TMRM accumulation in ρ0 cells is due to the existence of a Δψm.3.2. HK II detachment from mitochondria as a PTP-inducing strategy
As ρ0 cells lack oxidative phosphorylation, they must entirely rely
on glycolytic activity to generate ATP. Accordingly, we found that the
expression level of the ﬁrst enzyme of the glycolytic chain, hexoki-
nase, and in particular HK isoform II, which is upregulated in tumor
cells, was increased in 206 ρ0 cells compared to parental 143B ρ+
cells (Fig. 1C). A large fraction of HK II was located in mitochondria
(Fig. 1D), as already observed in tumor cell models [47,53]. Since un-
binding of HK II from the organelles prompts PTP opening [47], we in-
duced HK II detachment in order to assess the presence of a PTP in ρ0
cells. As a ﬁrst strategy, we used the drug clotrimazole (CTM), and
found that in ρ0 cells it both caused detachment of HK II (Fig. 2A) andoblot analysis of RC protein expression from complex V (CV) to complex I (CI) in 143B
+ and ρ0 cells loaded with 20 nM TMRM before (upper panels) and after (lower panels)
om ρ+ and ρ0 cells; D, immunoblot analysis showing a mitochondria-bound fraction of
ito) before (−) or after (+) treatment with 2 μg trypsin every 70 μg of mitochondria.
re endoplasmic reticulum, nucleus and cytosol markers, respectively, used to assess the
rane and of the intermembrane space, respectively, whereas prohibitin and CyP-D are
Fig. 2. Treatment with CTM induces detachment of HK II from mitochondria and mitochondrial depolarization in 206 human osteosarcoma ρ0 cells. A, immunoblot analysis of HK II
expression in total lysates (Tot), cytosolic (Cyto) or mitochondrial fractions (Mito) before (−) or after (+) treatment with 50 μM CTM for 1 h; the mitochondrial fraction was subjected
to trypsinization at 4 °C for 1 h at a mitochondria:trypsin ratio of 35:1 (w/w); prohibitin is used as a mitochondrial loading control. B, C, TMRM epiﬂuorescence intensity of 206 ρ0 (panel
B) and 143B ρ+ (panel C) cells; where indicated 10 μM CTM and 4 μM FCCP were added in the absence (closed symbols) or presence (panel B, open symbols) of 1.6 μM CsA.
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staining performed with epiﬂuorescencemicroscopy (Fig. 2B), whereas
it was ineffective in ρ+ cells (Fig. 2C). Notably, preincubation with CsA,
a drug that targets the PTP regulator CyP-D,markedly delayed themito-
chondrial depolarization induced by CTM (Fig. 2B). In parallel, we used
aHK II-derived peptide (TAT-HK II)made cell permeant through linking
with a hydrophobic stretch of the HIV-1 TAT protein, which displacesFig. 3. The TAT-HK II peptide induces HK II detachment from mitochondria and the ensuing
immunoblot analysis of HKII expression in cytosolic (Cyto) and mitochondrial (Mito) fractio
fraction was subjected to trypsinization at 4 °C for 1 h at a mitochondria:trypsin ratio of 35
cence intensity of 143B ρ+ (panel B) and 206 ρ0 cells (panel C) cells; where indicated 5 μM
added. D, output of multiparametric FACS analysis showing the TMRM ﬂuorescence intensity
after treatment with 1.6 μM CsA (panel b), 2.5 μM TAT-HK II peptide (panel c) or 2.5 μM TAT-HK
ﬂuorescence intensity of ρ0 cells; where indicated, 2.5 μM TAT-HK II peptide was added to naiveHK II from mitochondria with very high selectivity [47]. After having
conﬁrmed the effect of the peptide on HK II binding to mitochondria
of ρ0 cells (Fig. 3A), in keeping with the CTM data, we found that TAT-
HK IIwas unable to affectΔψm of 143B ρ+ cells (Fig. 3B), but it triggered
a rapid mitochondrial depolarization in 206 ρ0 cells (Fig. 3C–E). Again,
cell pretreatment with CsA markedly inhibited the effect of TAT-HK II
(Fig. 3D–E). Taken together, these data indicate that 206 ρ0 cells aremitochondrial depolarization and PTP opening in 206 human osteosarcoma ρ0 cells. A,
ns treated with TAT-Ctrl peptide (−) or TAT-HK II peptide (+) for 1 h; mitochondrial
:1 (w/w); prohibitin is used as a mitochondrial loading control. B,C, TMRM epiﬂuores-
TAT-HK II peptide (closed symbols) or 5 μM TAT-Ctrl peptide (open symbols) were
and forward light scattering (FSC-A) of ρ0 cells in the absence of additions (panel a) and
II peptide in cells pretreated with 1.6 μM CsA (panel d). E, kinetic FACS analysis of TMRM
cells (closed symbols) or to cells that had been treated with 1.6 μM CsA (open symbols).
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mitochondrial detachment of the HK II enzyme.
3.3. Nutrient starvation is another way to induce PTP opening in 206 ρ0
cells
We and others have recently shown that PTP opening is regulated
in tumor cell models by an ERK/GSK3/CyP-D transduction axis; in mi-
tochondria, GSK3 favors PTP opening by phosphorylating CyP-D, but a
constitutively active ERK opposes this signalling by phosphorylating
and inhibiting GSK3 [48,49]. Therefore, we tried to elicit PTP opening
by exposing 206 ρ0 cells to starvation through serum and glucose de-
pletion, thus blocking ERK and triggering this transduction pathway.
As expected, in these conditions we observed both ERK inhibition
and GSK3 activation (Fig. 4A; active ERK1/2 is Ser/Thr phosphorylated,
whereas active GSK3α/β is Ser/Thr dephosphorylated). Moreover, 206
ρ0 cells underwent a rapid mitochondrial depolarization that was sensi-
tive to CsA (Fig. 4B); remarkably, in 143B ρ+ cells a 4 hour serum and
glucose depletion was unable to induce major changes in the ERK/
GSK3 signaling axis (Fig. 4A), and these cells did not undergo any mito-
chondrial depolarization (Fig. 4B). To better assess the role played by
ERK and GSK3 in PTP opening of 206 ρ0 cells, we explored the presence
of a mitochondrial fraction of these enzymes. As reported in Fig. 4C, we
could ﬁndboth ERK1/2 andGSK3α/β in 206 ρ0mitochondria, andmod-
ulation of their activity in mitochondria following serum and glucose
depletion paralleled that observed in the whole cells; in addition, a
partial tryptic digestion of the mitochondrial fraction revealed that
both kinases are located in thematrix, as they display a pattern of tryp-
sin resistance similar to that of matrix prohibitin (Fig. 4D). In accord
with an enhancing role played on PTP opening by GSK3-dependentFig. 4. FBS/glucose depletion of 206 human osteosarcoma ρ0 cells triggers PTP opening and c
of 143B ρ+ and 206 ρ0 cells before (lanes marked 0) and after the indicated times of FBS/gluc
determined on the lack of staining with TMRM, see Fig. 3C) under basal conditions (Ctrl) or a
subcellular fractions of ρ0 cells incubated for 2 h in the presence (+) or absence (−) of FBS
total lysates (Tot), cytosolic (Cyto) or mitochondrial fractions (Mito) before (lanes marked 0
reticulum, nucleus, cytosol and mitochondrial markers are as described in Fig. 1. E, Phospho-
FBS and glucose for 2 h. Blot probing with CyP-D is shown, and IgG and input of CyP-D ar
depleted or not for 6 hours of FBS and glucose; IND is the GSK3α/β inhibitor indirubin-3′-ophosphorylation of CyP-D,we observed that CyP-D is Ser/Thr phosphor-
ylated in 206 ρ0 cells after serum and glucose starvation (Fig. 4E), and
that the GSK3 inhibitor indirubin-3′-oxime inhibited cell death in these
conditions (Fig. 4F).
Notably, when 206 ρ0 cells were depleted of serum and glucose
we could observe HK II detachment frommitochondria (Fig. 4C), sug-
gesting that these conditions might converge on a PTP-opening signal
that involves HK II partition between mitochondria and cytosol.
4. Discussion
In the present manuscript we have shown (i) that ρ0 cells can un-
dergo a CsA-sensitive permeability transition; (ii) that opening of
the PTP plays a role in cell death caused by HK II detachment frommi-
tochondria and by glucose and serum deprivation; and (iii) that ρ0
cells undergo adaptive changes that are remarkably similar to those
of highly glycolytic tumor cells such as increased expression of HK II
on the mitochondrial outer membrane and regulation of PTP opening
through GSK3-dependent Ser/Thr phosphorylation of CyP-D.
The occurrence of PTP opening in ρ0 cells is debated: two studies
could not ﬁnd protective effects of CsA on either cell death induced by
staurosporine [13] or on caspase-3 activation induced by thapsigargin
[18]. Yet, a negative result cannot rule out with certainty a role of the
PTP. Indeed, CsA desensitizes but does not block the pore [54], which
may be very prone to opening in ρ0 cells given (i) their lower Δψm
[9,11] and (ii) the voltage-dependence of the PTP [55], which in ρ0
cells may be poised very close to the resting potential. Here we demon-
strate that CsA can inhibit mitochondrial depolarization induced in ρ0
cells both by HK II detachment and by serum and glucose depletion.
These results strongly argue in favor of the existence of a PTP in cellsell death through the phosphorylation of CyP-D. A, immunoblot analysis of total lysates
ose depletion. B, FACS analysis of the number of cells with depolarized mitochondria (as
fter 1 h of FBS/glucose depletion with or without 1.6 μM CsA. C, immunoblot analysis of
/glucose. D, immunoblot analysis of the subcellular expression of ERK and GSK3α/β in
) or after treatment with 2 or 4 μg of trypsin every 70 μg of mitochondria. Endoplasmic
Ser/Thr immunoprecipitations on lysates from ρ0 cells kept in medium with or without
e reported as loading controls. F, FACS analysis of annexin V-FITC staining of ρ0 cells
xime. Mean ﬂuorescence is plotted as fold change compared to control.
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pensable for PTP induction.
The observation that ρ0 cells are more sensitive than ρ+ cells to
the PTP-inducing effects of HK II detachment could ﬁnd a reasonable
explanation within the framework of the PTP voltage-dependence
[55] and in the light of previous studies on the genesis of the Δψm in
ρ0 cells [9,11]. Although the F1F0 ATP synthase of ρ0 cells does not
pump protons it is catalytically active as an ATP hydrolase, and this
activity is essential to maintain a gradient of ATP between the cytosol
and the matrix allowing the electrogenic exchange of extramitochon-
drial ATP formatrix ADP,which generates theΔψm [9]. Sensitive isotope
distribution techniques allowed to determine the Δψm of ρ0 cells to
≈−67 mV, which is about half of that maintained by parental ρ+ cells
under the same experimental conditions [11]. This means that the rest-
ing potential of ρ0 cells is closer to the voltage threshold for PTP open-
ing, which is therefore easily activated as soon as HK II is removed
from the outer membrane. Remarkably, in ρ0 cells binding of HK II to
the outer membrane of mitochondria is upregulated and contributes
to inhibition of outer membrane permeabilization via either the Bax
pathway or the permeability transition [47,56]. Thus, increased mito-
chondrial HK II in ρ0 cells appears as a protective mechanism meant
to counteract PTP opening, which is rapidly induced when HK II is de-
tached from mitochondria with either CTM or a HK II-derived peptide.
Why should PTP opening be detrimental in mitochondria that do
not pump protons across the inner mitochondrial membrane? The
very existence of a Δψm implies that the inner membrane permeabil-
ity of ρ0 cells is low enough for charge separation to occur. It has been
calculated that mitochondria in ρ0 cells utilize≈13% of the total gly-
colytic ﬂux to maintain Δψm; and that this ﬂux is ≈18% of the maxi-
mal ATP hydrolytic capacity of mitochondria as measured after
permeabilization [11]. This means that PTP opening can increase the
mitochondrial ATP hydrolytic rate up to ﬁve fold, thus drawing an in-
creased fraction of the glycolytic ATP ﬂux and contributing to ATP
depletion.
It is becoming increasingly clear that the PTP is the terminal effector
of several signal transduction modules, including organelle-restricted
kinases and phosphatases [29]. We and others have recently shown
that signalling through mitochondrial ERK and GSK3 contributes to
the anti-apoptotic phenotype of tumor cells through PTP inhibition con-
veyed by modulation of Ser/Thr CyP-D phosphorylation [48,49]. Our
present ﬁndings of a similar regulatory pattern of CyP-D in ρ0 cells fur-
ther extend the interest in this model to understand the antiapoptotic
defence mechanisms of highly glycolytic tumor cells.Acknowledgements
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